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ABSTRACT
Hypericum perforatum as an Antimycobacterial Agent and Its Implications
as an Additional Tuberculosis Medication
by
Trent W. Mortensen, Master of Science
Utah State University, 2010
Major Professor: Dr. Charles D. Miller
Department: Biological Engineering
An immediate demand exists for new tuberculosis (TB) antibiotics due to the
ever-increasing spread of drug-resistant strains. The drug-development process goes
through four phases, the first (Phase 0) of which is to demonstrate and investigate drug
effectiveness and toxicity. This research investigated the effectiveness of the Hypericum
perforatum herb (commonly St. John’s wort (SJW)) in its growth inhibition of
mycobacteria and its viability effect on human lung cells.
Organic-solvent SJW extracts were effective at inhibiting every nonpathogenic
genetically sequenced Mycobacterium isolate currently available (six isolates) in
preliminary studies. Quantitative studies of five Mycobacterium isolates showed an order
of concentration sensitivity to the SJW methanol (MeOH) extract as (high to low) M.
JLS, M. KMS, M. phlei (not sequenced), M. MCS, B. subtilis, M. smegmatis, and E. coli,
with minimal bactericidal concentrations (MBCs) ranging from 0.33-2.66 mg extract/ml.
The SJW compounds hyperforin (Hfn), hypericin (Hpn), and pseudohypericin (Phn) were
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quantified using a novel HPLC method that utilized common HPLC equipment. A crude
MeOH extract solution of 133 mg extract/ml contained 2.26 mg Hfn/ml, 0.77 mg
Hpn/ml, and 2.67 mg Phn/ml. Purified Hfn had a MBC of between 6-13 µg/ml for M.
JLS in the absence of Tween 80. Tween 80 repressed Hfn (46 µg/ml) inhibition of M.
JLS at ≥ 0.025% (v/v). Purified Hpn and Phn showed no inhibition of M. JLS at all
assayed concentrations, which were ≤ 27 µg/ml and ≤ 25 µg/ml, respectively. Inhibitory
results from the five quantitatively assayed Mycobacterium samples could be
extrapolated to M. tuberculosis, as these isolates have as high as 72% genetic homology
to the pathogen.
The crude MeOH extract and Hfn were lethal to the human carcinomic alveolar
epithelial lung cell line A549 at 1.3 mg extract/ml (crude extract) and ≥ 11 µg/ml (Hfn),
with a Hfn LD50 of 3-6 µg/ml (5.6-11.2 µmol/L). Because Hfn is antiproliferative to a
list of other carcinomic cell lines in the same concentration range, the A549 cell line may
be added to that list. The addition of M. JLS cells (5x106 cells/cm2) to penicillinstreptomycin-containing A549 culture (which killed the bacteria) did not affect A549
viability.

(140 pages)
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CHAPTER 1
INTRODUCTION
The Need for Additional Mycobacterial Antibiotics
The Global Tuberculosis Problem
Among diseases caused by the genus Mycobacterium, tuberculosis (TB) is the
most common. This infectious disease is caused by Mycobacterium tuberculosis and
affects about one-third of the world’s population. About 10% of those infected develop
the active form of the disease in their lifetime, which usually results in pulmonary (lung)
infection but can also infect other areas of the body (Smith, 2003). Those who do not
develop the active disease maintain the latent disease (Jasmer et al., 2002). In 2008,
there were 9.4 million new TB cases and 1.8 million TB-related deaths (WHO, 2009).
TB treatment has gone through several stages, from the fresh-air sanatoriums of
the 19th century to the chemotherapeutic treatments of today (Snider, 1997). Current
treatment regimens rely on strategies utilizing first- and second-line drugs, with the firstline drugs being more effective and having fewer side effects (Blumberg et al., 2003).
Lack of adherence to drug regimens has led to the evolution of drug-resistant TB strains
that do not respond to the best first-line medications and, in some cases, the best secondline medications (Sharma and Mohan, 2006; CDC, 2010). Therefore, novel TB
medications are needed that shorten regimen duration and improve the treatment of drugresistant and latent TB (O’Brien and Nunn, 2001). The purpose of this research was to
investigate the feasibility of using the Hypericum perforatum herb (or more commonly
St. John’s wort) for producing such medications. 	
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Hypothesis
The Hypericum perforatum herb contains quantifiable compounds that cause cell
death of Mycobacterium isolates but not of human lung cells.
Objectives
1. Establish an efficient, accurate, and precise high-performance liquid
chromatography (HPLC) method for quantification of the SJW compounds
pseudohypericin, hyperforin, and hypericin.
2. Demonstrate inhibitory effectiveness of SJW compounds on mycobacteria and
determine the effective concentrations.
3. Determine the effect of SJW compounds on the viability of human alveolar
epithelial cells.
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CHAPTER 2
REVIEW OF LITERATURE
	
  

Mycobacteria
Genus Properties
M. tuberculosis and others of the genus Mycobacterium have distinct properties
that set them apart from other bacteria. With regard to scientific classification,
mycobacteria are their own family, Mycobacteriaceae, under the suborder
Corynebacterineae, under the order Actinomycetales, under the phylum Actinobacteria in
the Bacteria kingdom (NCBI, 2010).
Mycobacteria are aerobic and generally nonmotile. Since this genus does not
retain a crystal-violet stain, it is classified as an acid-fast Gram-positive bacteria because
it does not have an outer membrane. Mycobacteria have characteristically thick, waxy,
cell walls largely composed of mycolic acids. This cell wall is composed of the
following layers (from outer to inner): outer layer (capsule) lipid, mycolic acid,
arabinogalactan polysaccharide, peptidoglycan, periplasm, and plasma membrane (Daffe
and Reyrat, 2008). Mycobacteria are bacilli that can range in size from 0.2-0.7 µm wide
and 1.0-10 µm long (Holt et al., 1994). They can be classified in their pigmentation as
follows: photochromagens, which produce non-pigmented colonies in the dark and
pigmented colonies in the light, scotochromogens, which always produce deep yellow or
orange colonies, and non-chromogens, which have a pale yellow or tan color (M.
tuberculosis is of this type) (Jenkins, 1981). Mycobacteria can be found in water, soil, or
animal tissues or secretions.
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Mycobacteria are relatively slow growing, with those that form visible colonies
within seven days being called rapid growers, and those taking longer being called slow
growers (Wayne and Kubica, 1986). They are relatively flexible in their growth
conditions, with growth temperatures (depending on strain) ranging from 25˚C to over
50˚C and the ability to grow on several types of media with simple nitrogen, carbon, and
energy sources (Allen, 1998). Tween 80, a surfactant, is often added to mycobacterial
liquid cultures to lessen clumping, which is often an issue. However, Tween 80 can also
alter the outmost layer of the cell wall (Parish and Stoker, 1998).
Mycobacteria are known to have functional secretion pathways, including Sec,
Tat, and mycobacterial-specific pathways, with orthologs of all known necessary
secretion proteins for these pathways present in mycobacterial genomes. Secreted
proteins in pathogenic mycobacteria play an important part in their virulence (McCann et
al., 2009).
According to the National Center for Biotechnology Information (NCBI, 2010),
there are 40 completely sequenced genome variations of 14 mycobacterium species, M.
tuberculosis having 22 variations. There are only six nonpathogenic Mycobacterium
isolates in that database, all of which are considered rapid growers: M. smegmatis, M.
gilvum PYR-GCK, M. vanbaalenii PYR-1, M. JLS, M. KMS, and M. MCS. The latter
five isolates are known for their ability to mineralize polyaromatic hydrocarbons (PAHs),
with the latter three of these having been isolated by researchers at Utah State University
(Miller et al., 2004, 2007).
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Tuberculosis
Prevalence
As of 2009, information provided by the World Health Organization (WHO)
states that TB infects one-third of the world’s population, and that 10% of those infected
will develop the active form of TB sometime during their lifetime. Those with active TB
each infect 10-15 people, on average. TB has the highest incidence in areas of poverty
and is a leading cause of death for Human Immunodeficiency Virus (HIV)-positive
people, making HIV-infected persons 20 to 40 times more susceptible to active TB
development (WHO, 2009).
Pathogenesis
While much about the mechanism of action for the virulence of M. tuberculosis,
the pathogen that causes TB, remains to be learned, reviews on the subject by van Crevel
et al. (2002) and Smith (2003) are informative. The severity of virulence can range from
the potent, disseminating miliary tuberculosis to the self-limiting tuberculosis pleuritis
(Smith, 2003). Infecting M. tuberculosis bacilli can take localization in many parts of the
body, but usually takes residence in the lungs. In a 1978 study (prior to the AIDS
epidemic), it was shown that 85% of newly acquired TB cases resulted in pulmonary
infection (Hopewell, 1994). This is similar to a 1993 survey of 313 TB patients, which
showed 81% of the cases as pulmonary (Miller et al., 2000).
The events leading up to the final infection state have been studied. The
chronology of TB pathogenesis has been organized into four stages (Dannenberg and
Rook, 1994; Smith, 2003). (1) The first stage, lasting 3 to 8 weeks, begins with the
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inhalation of aerosols containing M. tuberculosis. The bacilli are transferred to lung
lymph nodes once they reach the alveoli. This creates the primary, or Ghon, complex.
Whether or not it is possible for host macrophages to ingest and destroy the bacteria at
this point depends on the bactericidal ability of the macrophages and on the TB virulence.
(2) If the mycobacteria survive this step, then monocytes in the blood and other
inflammatory cells come to the infection sites in the lung. This second stage, or
spreading stage, lasts about three months and consists of hematogenous spread the
mycobacteria to other parts of the lungs or other organs. This stage also consists of
monocyte differentiation into macrophages and subsequent ingestion (but unsuccessful
destruction) of the mycobacteria. This creates a cycle of increasing numbers of both
macrophages and mycobacteria.
Two to three weeks after infection, T-cell lymphocytes arrive at the infection
sites, called tubercles, and activate the macrophages to destroy the mycobacteria they
have ingested. This leads to the third stage (3), or inflammation stage, which begins with
the stop of logarithmic mycobacterial growth and can last for 3 to 7 months. Granulomas
are formed at the infection sites, with caseous centers consisting of dead macrophages
that are filled with mycobacteria and an encasing of fibroblasts, lymphocytes, and bloodderived monocytes (Smith, 2003). The last stage (4), or slowing stage, can last for up to
three years. In this stage, the infection may become dormant or it may spread later in life,
depending on immune system strength. If the immune system weakens, mycobacteria in
the granulomas may rupture their containment, leaking into the outside environment.
This can lead to infection elsewhere in the lungs or body. If this happens, the outcome of
this final stage event depends on the balance between (i) the outgrowth and killing of M.
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tuberculosis and (ii) the extent of tissue necrosis, fibrosis, and regeneration (van Crevel et
al., 2002).
Symptoms and Methods of Diagnosis
Symptoms. Miller et al. (2000) described the most common TB symptoms in a
1993 survey of 313 TB patients in Los Angeles County, CA, USA. With 81% of the
cases pulmonary, common symptoms, in order of prevalence, were as follows: cough,
fever, fatigue, weight loss, sweats, anorexia, chest pain, diarrhea, and hemoptysis
(coughing up blood). Several of the symptoms were present for more than 2 weeks.
Mantoux Tuberculin Skin Test. According to the Mayo Clinic (2009) and Jasmer
et al. (2002), testing for TB is done first using one or both of two tests, which are also the
only current means of diagnosing latent TB. The first test is the Mantoux tuberculin skin
test, which tests for a visual immune response to the purified protein derivative (PPD) of
M. tuberculosis when this derivative is injected intracutaneously. The level of immune
response is determined by measuring the induration (hardened skin) diameter at the
injection site, not the erythema (redness).
Whole Blood Interferon-γ Assay. The second test is the whole blood interferon-γ
assay. This assay tests for the presence of interferon-γ from T-lymphocytes, which have
been produced in response to exposure to M. tuberculosis PPD. Another version of this
test uses a different M. tuberculosis antigen, ESAT-6, to test for release of interferon-γ if
the first form of the blood test has complications, such as can be caused by BCG
(Bacillus Calmette Guerin TB vaccine) (Jasmer et al., 2002).
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Active TB Suspected. The Mayo Clinic (2009) states that if active TB is
suspected, follow-up tests could include chest X-ray, computerized tomography (CT)
scan, culture tests, or nuclear acid amplification (NAA) tests. The latter test utilizes
polymerase chain reaction (PCR) to amplify and detect genes unique to drug-resistant
strains.
Treatment
Brief History. Scheindlin (2006) gave an overview of the history of TB treatment.
TB treatment first saw some success with the use of fresh-air sanatoriums in the early-tomid 1900s, which were places of retreat (usually in the mountains) where a healthy
atmosphere aided in recovery for victims by allowing the immune system to quarantine
M. tuberculosis bacilli into granulomas without additional infection. The discovery and
isolation of M. tuberculosis by Robert Koch led to the development of the first TB
antibiotic, streptomycin, by Waksman in 1943. Several other antibiotics were produced
over the next 23 years, including isoniazid, pyrazinamide, ethambutol, and rifampicin.
First- and Second-Line TB Antibiotics. Shah et al. (2007) stated that first-line
antibiotics for TB today are mainly isoniazid (INH), rifampicin (RIF), ethambutol
(EMB), and streptomycin (SM), with the Merck Manual (2009) adding rifabutin,
rifapentine, and pyrazinamide (PZA) to this list. Second-line drugs have been organized
into six classes: (1) aminoglycosides other than SM (e.g., kanamycin and amikacin), (2)
cyclic polypeptides (e.g., capreomycin), (3) fluoroquinolones (e.g., ofloxacin,
ciprofloxacin, levofloxacin, and moxifloxacin), (4) thioamides (e.g., prothionamide and
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ethionamide), (5) serine analogs (e.g., cycloserine and terizidone), and (6) salicylic acid
derivatives (e.g., para-aminosalacylic acid)” (Shah et al., 2007).
Mechanisms of Action of First-Line Antibiotics. TB antibiotics cause
mycobacterial inhibition through one or more of several mechanisms of action. INH
receives peroxidative activation by the mycobacterial enzyme KatG, which forms species
with NAD+ and NADP+ that inhibit enzymes that synthesize lipids and nucleic acids. It
also forms nitric oxide species that inhibit metabolic enzymes (Timmins and Deretic,
2006). One of the end results of INH activity is the inhibition of mycolic acid synthesis
(Mayer, 2010). RIF binds bacterial RNA polymerase, preventing RNA transcription
(Wherli, 1983). EMB interferes with arabinan biosynthesis in the cell wall (Dover et al.,
2008). SM interferes with aminoacyl-tRNA decoding, interfering with protein synthesis
(Rattan et al., 1998). It is proposed that PZA inhibits fatty acid synthase (Dover et al.,
2008).
Treatment Regimens. The American Thoracic Society (ATS), Centers for Disease
Control and Prevention (CDC), and Infectious Diseases Society of America (IDSA) have
produced an extensive document outlining recommended treatment regimens for TB
cases of various types and giving detailed information on medications, medication
combinations, and special treatment considerations for various patient subgroups
(Blumberg et al., 2003). While this information is too lengthy to be reviewed in detail
here, it may be generally stated that treatment for drug-susceptible TB typically begins
with two or more of the first-line drugs, including INH and RIF. Initial treatment
regimens depend on suspicion of severity and the presence of additional medical
conditions, such as HIV. Treatment then progresses to one of various other treatment
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regimens depending on test results. If drug-resistant TB is confirmed, treatment regimens
employ at least three drugs to which the TB strain is susceptible in vitro.
Drug-Resistant TB Strains
Resistance Development. Drug-resistant strains of TB have emerged over time
due to the lack of adherence to drug regimens (Pablos-Mendez and Lessnau, 2000).
When all of the TB bacilli are not destroyed, they can multiply and in rare cases develop
a genetic mutation either through DNA replication or through gene transfer from another
organism, which counters the mechanism of action of an antibiotic. Such has been the
case with several TB antibiotics, including INH and RIF of the first-line drugs and
fluoroquinolones and the injectable drugs of the second-line medications (Rattan et al.,
1998). Mutations have occurred in at least four enzyme-coding regions of M.
tuberculosis, resulting in previously-targeted enzymes with altered binding sites to which
isoniazid can no longer bind to prevent synthesis of mycolic acid. Mutations have also
occurred in the DNA region coding for the RNA polymerase β subunit, which is the
binding target for rifampicin. Once mutated a certain way, rifampicin can no longer bind
to this subunit, and transcription goes on as usual in the cell (Sharma and Mohan, 2004).
MDR-TB and XDR-TB. In the early 1990’s, multi-drug resistant TB (MDR-TB)
was discovered (Shah et al., 2007) and is defined as resistance to at least the first-line
drugs RIF and INH (Sharma and Mohan, 2004). In 2006, a report was jointly produced
by the CDC and WHO describing the emergence of extensively drug-resistant TB (XDRTB) (CDC, 2006). XDR-TB is defined as resistance to at least RIF and INH among firstline drugs, resistance to any fluoroquinolone, and resistance to at least one second-line
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injectable drug (amikacin, capreomycin, or kanamycin). By November 2009, 57
countries reported at least one case of XDR-TB (WHO, 2009). Preliminary anecdotal
evidence has also suggested some TB cases in Europe classified as extremely drugresistant, or XXDR (Migliori et al., 2007).
The Call for Novel TB Medications
In the 2002 American Thoracic Society (ATS) report, there is a call for novel
drugs to treat TB, both drug-susceptible and drug-resistant (Blumberg et al., 2003).
There are three reasons stated for this call: (1) the current lengthy treatment regimens,
which last for at least 6 months and which lead to non-adherence (which contributes to
unsuccessful treatment and drug resistance), (2) the increasing rate of drug-resistant TB
(Espinal et al., 2001), and (3) the need for more effective treatment of latent TB infection
(LTBI). This need is not only due to the difficulty in producing new medications, but in
large part to the lack of urgency felt by pharmaceutical companies (O’Brien and Vernon,
1998; O’Brien and Nunn, 2001).
Drug Development and Toxicity Testing
Minimal Inhibitory Concentrations and
Minimal Bactericidal Concentrations
An important first step in developing a novel antibiotic is to know effective
dosage concentrations. Due to the variety of methods researchers have used in
determining minimal inhibitory concentrations (MICs) and minimal bactericidal
concentrations (MBCs), Andrews (2001) set forth methods to enable clear comparison of
various antibiotics. She defined MIC as the lowest concentration that will inhibit growth
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after overnight incubation and MBC as the lowest concentration that will inhibit growth
after subculture onto antibiotic-free media. This definition cannot be strictly applied to
mycobacteria, however, due to their relatively slow growth rates. (Wayne and Kubica,
1994; Miller et al., 2004).
Phases of Drug Development
According to the United States Food and Drug Administration (FDA, 2010),
Pacific Biolabs (PBL, 2009), and Chien et al. (2005), the process of new drug
development goes through three clinical phases (after the preclinical phase) before it can
be marketed. DiMasi et al. (2003) gave mean durations of and times between the clinical
phases. Phase 0 is the preclinical phase. This phase includes identification of a potential
pharmaceutical compound, demonstration of its (or other compounds of the same
pharmacophore) effectiveness in cell or tissue cultures, gathering of toxicity data to
determine dosage ranges, compound characterization, animal testing, and identification of
a lead compound for clinical testing. Phase I (mean of 21.6 months), the first clinical
phase, is a small-scale study on a group of healthy people to evaluate dosage and
pharmacokinetic parameters and observe any toxicity indicators. Phase II (mean of 25.7
months) is a larger scale study (100-250 patients) used to demonstrate effectiveness in the
intended population, gain information on side effects, and establish dosages for Phase III.
Phase III (mean of 30.5 months) is a large-scale study used to gather additional data on
efficacy and safety of the new drug. Once this phase has been completed, a Biologics
License Application (BLA) or New Drug Application (NDA) is submitted to the FDA. If
approved, the new pharmaceutical can proceed to the marketing phase.
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Hypericum perforatum (St. John’s Wort)
Background
Hypericum perforatum, or St. John’s wort (SJW), is a perennial herb of the family
Hypericaceae that is found in many temperate regions throughout the world. This herb is
considered an invasive species in many areas and grows to a height 0.3-1 m on average.
Its leaves, 1.5-4 cm long, have pellucid glands (hence the “perforatum,” Latin for
“perforated”). Each plant produces seed pods and as many as 100 yellow flowers during
the spring, with each flower consisting of five pedals that are usually 8-12 mm long
(Kirakosyan, 2006). The highest concentrations of bioactive components are found in the
aerial parts of the plant, especially the generative parts, and vary in their concentration
throughout the year (Southwell and Bourke, 2001; Butterweck, 2009).
St. John’s Wort – Active Compounds
Several bioactive compounds in SJW have been identified and investigated
(Greeson et al., 2001). Hypericin (Hpn) and pseudohypericin (Phn), which are
napthodianthrones, and hyperforin (Hfn), a phloroglucinol, have been subjects of a
substantial portion of SJW research focus because of their implications in human health.
Their concentrations in SJW can vary greatly depending on variables such as harvesting
time, temperature, and germplasm (Couceiro et al., 2006). Chemical structures for these
compounds are shown in Figure 2.1 (Bauer et al., 2001).
The Phloroglucinol Hyperforin. Hfn has been the subject of much research for its
antidepressant (Gaster and Holroyd, 2000; Southwell and Bourke, 2001; Muller, 2003;
Lawvere and Mahoney, 2005; Medina et al., 2006), anticancer (Agostinis et al., 2002;
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Schempp et al., 2002; Hostanska et al., 2003; Quiney et al., 2007), anti-inflammatory
(Tedeschi et al., 2003; Medina et al., 2006), and antibiotic activity (Gurevich et al., 1971;
Laakmann et al., 1998; Ebrey, 1999; Schempp et al., 1999; Reichling et al., 2001; Avato
et al., 2004; Zanoli, 2004; Beerhues, 2006; Medina et al., 2006; Milosevic and Solujic,
2006). In humans, Hfn has been found to reach blood concentrations of approximately
400 ng/ml 3-3.5 hr after a 1200 mg administration of a 5% Hfn SJW extract (Biber et al.,
1998). The maximum absorbance wavelength for this compound varies depending on pH
and solvent used, but 270 nm is typically used for analysis (Ganzera et al., 2002;
Fourneron and Nait-Si, 2006). Hfn is soluble in organic solvents but completely
insoluble in water (Holzl and Petersen, 2003).
The Napthodianthrones Hypericin and Pseudohypericin. Hpn and Phn (often
grouped together as “hypericins”) are photoactive compounds (Pace, 1942; Greeson et
al., 2001; Southwell and Bourke, 2001; Muller, 2003) and in some instances have been
reported as antibiotic compounds (Avato et al., 2004; Milosevic and Solujic, 2006).
However, the antimicrobial effect of Hpn “seems to be directly related to the
simultaneous effects of radiation from the sun” (Reichling et al., 2001). Hpn has also
been claimed to work synergistically with Hfn in causing apoptosis in human malignant
cells (Hostanska et al., 2003). Phn and Hpn are also the antiviral/antiretroviral
components of SJW (Meruelo et al., 1988; Lavie et al., 1989; Jacobson et al., 2001).
In SJW extracts, Phn is typically found in concentrations two to four times higher
than Hpn but can be up to ten times higher (Butterweck, 2009). These compounds are
fluorescent with excitation and emission spectra dependent on solvent type used (Wynn
and Cotton, 1995) and pH (Yamazaki et al., 1993) but are usually assayed at or around
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(excitation/emission) 315/590 nm (Bauer et al., 2001; de los Reyes and Koda, 2001).
Absorption spectra is also pH and solvent dependent but is typically assayed at or around
590 nm (Yamazaki et al., 1993, Nait-Si and Fourneron, 2004). The solubility of Hpn at
30ºC is 500 µg/ml in methanol (MeOH) and 40 µg/ml (considered insoluble) in water.
Aqueous solubility of Hpn can be increased to 30% that of MeOH by adding 2hydroxypropyl-β-cyclodextrin (Holzl and Petersen, 2003). The hypericins are also
soluble in an ethanol (EtOH) aqueous solution up to a dilution of 25:75 EtOH:H2O,
beyond which point colloids form (Gaind and Ganjoo, 1959). Hpn and Phn are insoluble
in water at ambient temperature but can be more than 40% extracted in an aqueous tea at
temperatures of 60-80ºC (Butterweck, 2009). Phn is slightly more soluble in polar
solvents due to the extra hydroxyl unit in its chemical structure (Kirakosyan, 2006;
Karioti and Bilia, 2010).
Hypericin Photodynamic Therapy. Hpn is one of the most potent naturally
occurring photodynamic agents and is being researched for use as a photodynamic
therapy (PDT) agent. Hpn can cause both apoptosis and necrosis, depending on
concentration and dose of light (Agostinis et al., 2002), with apoptosis occurring at lower
Hpn concentrations than necrosis (Karioti and Bilia, 2010). This compound is excited
and becomes cytotoxic by wavelengths between 590-600 nm. It inhibits protein kinase
C, irreversibly damages the sarco/endoplasmic reticulum and other cellular membranes,
decreases cellular pH, and inhibits mitochondrial function (Sigma-Aldrich, 2009). Hpn is
of great interest to the field of oncology because of the potential for direct, non-systemic
cancer treatment. The mode of operation has been described for Hpn PDT, which
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ultimately leads to reactive oxygen species (ROS) and subsequent oxidative tissue
damage (Agostinis et al., 2002; Kiesslich et al., 2006; Karioti and Bilia, 2010). Though
Phn is similar in chemical structure to Hpn, studies suggest that Phn is not the
photosensitizer (Vandenbogaerde et al., 1998).
Compound Preservation and Photoconversion. Hfn is known to be unstable and
degrade in the presence of light or oxygen (Gray et al., 2000; Orth and Shmidt, 2000). A
study by de los Reyes and Koda (2001) investigated different solvent types for
minimizing Hfn degradation. It was found that using acidified MeOH (pH 2.5 with
orthophosphoric acid) for the extraction solvent preserved Hfn better than pure MeOH,
especially at colder temperatures. Other authors performed studies in the dark to preserve
Hfn from light degradation (Avato et al., 2004). While Hfn requires protection from
light, Hpn and Phn require some exposure to light to allow the conversion of their
protoforms. It was found that storing a crude extract in an amber glass vial and exposing
to wavelengths in the range of 450-750 nm prevented Hfn degradation while allowing
conversion of the protoforms of Hpn and Phn; the optimal photoconversion range for
these compounds is 510-540 nm (Poutaraud et al., 2001b; Ruckert et al., 2007).
HPLC Quantification of SJW Compounds
The Need for Quantification
SJW is sold under various brand names and is sometimes weakly standardized,
usually according to Hpn content (de los Reyes and Koda, 2002). However, due to an
increase in research on the health benefits of other SJW bioactive compounds, there is a
push for greater regulation of these compounds as well. Several quantification
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techniques for SJW compounds exist, including two-dimensional proton nuclear
magnetic resonance (NMR) (which does not require compound separation for analysis)
(Bilia et al., 2001). However, high-performance liquid chromatography (HPLC) has been
the method of choice for quantification of these compounds (Vollmer and Rosenson,
2004), and efforts are still being made to develop improved HPLC methods.
Existing SJW HPLC Methods
Several HPLC methods have been developed for quantification of Hpn, Phn, and
Hfn. Many of these methods document thorough analysis of their accuracy and
reproducibility and would be effective in facilities with high-end HPLC separation and
detection equipment. However, small-laboratory-scale disadvantages of many of these
methods include calling for more than two mobile-phases (Mulinacci et al., 1999;
Bergonzi et al., 2001; Poutaraud et al., 2001a; Avato and Guglielmi, 2004), requiring
expensive or less-common analysis or detection equipment (Gray et al., 2000; de los
Reyes and Koda, 2001; Tolonen et al., 2002; de Jager et al., 2004; Tatsis et al., 2007), or
using relatively long run times (Bergonzi et al., 2001; Li and Fitzloff, 2001; Rager et al.,
2002). A large amount of research is conducted in laboratories with only a two-pump
HPLC system with diode array detection (DAD) and C18 column, and few methods
match these conditions. Some of the methods struggled to obtain sharp peaks with Hpn
and Phn. Ganzera et al. (2002) developed a method utilizing a less hydrophobic C12
column to sharpen the Hpn and Phn peaks. This method also used a two-pump/DAD
HPLC system and was a precise method. These authors tested several columns to find a
column adequate for efficient SJW compound quantification.
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SJW Antimicrobial Studies
SJW Extractions
Plant Parts Used in Extracts. The aerial parts of the SJW plant have usually been
used when authors have obtained their own plant materials for antimicrobial SJW studies
(Gaind and Ganjoo, 1959; Avato et al., 2004). After harvesting (and usually drying and
grounding) the plant material, various means have been taken to prepare crude SJW
extracts.
Solvents and Extraction Techniques. Solvents used in extracts have included
MeOH, EtOH, diethyl ether (Et2O), “petrol,” chloroform (CHCl3), acetonitrile (CH3CN,
or ACN), ethyl acetate (EtOAc), acetone ((CH3)2CO), n-butanol (C4H10O), dimethyl
sulfoxide (DMSO), and water. Extraction techniques using these solvents have included
Soxhlet extraction (Barbagallo and Chisari, 1987; Avato and Guglielmi, 2004),
sonication (Avato et al., 2004; Avato and Guglielmi, 2004), maceration (Osborn, 1943;
Avato and Guglielmi, 2004), digestion (Avato and Guglielmi, 2004), mixing (Yesilada et
al., 1999), and boiling with water (Reichling et al., 2001). In a study comparing the first
four extraction methods stated above, Avato and Guglielmi (2004) obtained the highest
extraction efficiencies with sonication.
Organisms Assayed and Results
MIC comparisons for all organisms from the above-mentioned studies are seen in
Table 2.1. The organisms assayed in these studies are listed in Table 2.2. All but the
studies performed by Barbagallo and Chisari (1987) and Reichling et al. (2001) reported
a much greater inhibition of Gram-positive strains than Gram-negative strains by SJW
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extracts and compounds. Some of these studies found that the essential oil, tanning
agents, and Hpn were not responsible for inhibition (Neuwald and Hagenstrom, 1954;
Gaind and Ganjoo, 1959), conflicting with the study of Avato et al. (2004), which
showed Hpn as having antimicrobial activity. No combination of pure compounds was
seen in any of these studies and merits investigation.
Human Alveolar Epithelial Cells (A549)
The A549 human alveolar epithelial cell line is a carcinomic, immortal cell line
isolated from a 58-year-old man with lung cancer (Giard et al., 1973). These cells
contain keratin, which is useful for staining purposes (ATCC, 2009). Due to their
carcinomic heritage, they can be perpetually subcultured, which makes them useful for
ongoing study. It is also possible to measure various inflammatory markers in these cells
in response to a treatment (Bhowmik et al., 2000). These cells have been found to be
relatively good models for a type of alveolar epithelial cells that are potential targets of
macromolecule drug delivery (Foster et al., 1998).
A study performed by Lin et al. (1998) attempted to mimic a M. tuberculosis
infection. This study investigated chemokine production in response to A549 cell contact
with M. tuberculosis cells. It was found that only treatment with living bacteria that were
able to achieve intracellular growth induced an inflammatory response.
Summary
In summary, MDR-TB and XDR-TB have reached a dangerous point. Mutations
in the genome of M. tuberculosis are making this bacterium increasingly resistant to
chemotherapy; therefore, new TB medications are needed. The SJW herb has shown
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inhibitory ability for several Gram-positive bacterial strains, but previous studies have
only included two mycobacterial isolates in SJW inhibitory assays (Table 2.2). As the
mycobacterial cell wall composition is different than that of other Gram-positive strains
(it contains more mycolic acid), SJW MIC and MBC values for Gram-positive strains
cannot be directly translated to mycobacteria. Therefore, direct studies of the effect of
SJW extracts and compounds on mycobacteria were performed in this research (Chapter
4). In order to determine inhibitory parameters, it is necessary to have accessible means
whereby SJW compounds can be quantified. While several SJW HPLC assays exist in
literature, there has been a lack of an assay that utilizes a two-pump HPLC system with
DAD detection, C18 column, and which does not take a large amount of time to
complete; such a method was developed during the course of this study (Chapter 3).
Finally, an effective antibiotic must not only be able to kill target bacteria, but must also
not harm the host. Blood Hfn levels after SJW ingestion do not reach concentrations
above literature MIC/MBC values of assayed Gram-positive bacteria. Therefore, other
methods for Hfn administration, such as inhalation, merit investigation. No study seen
thus far has assayed for effect of SJW extracts or compounds on human alveolar
epithelial cells (A549). Hence, this research also investigated the effect of SJW crude
extract and compounds on A549 viability (Chapter 5).
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Table 2.1 Literature MIC values of SJW (except Osborn’s study, which used Hypericum
elodes and Hypericum olympicum) extracts and pure compounds against Gram-positive
and Gram-negative bacteria. Gram-positive inhibition was dominant in most studies.
Author(s) (Year)

Extract or Pure Compound

Gram(+) MIC

Gram(-) MIC

Osborn (1943)

Ground herb pulp
(in H2O) (other Hypericum)

Not given, but inhibits

No inhibition

(CH3)2CO, Pet. Ether

Not given, but inhibits

No inhibition

Gaind & Ganjoo (1959)

CHCl3, (CH3)2CO, EtOH

1:104-1:102 dilution

No inhibition

Gurevich, et al. (1971)

Hyperforin

0.1-1.0 µg/ml

400 µg/ml

Barbagallo & Chisari
(1987)

CHCl3, H2O, MeOH, Petrol

0.31-1.25 mg extract/ml

1.25-2.5 mg
extract/ml

Schempp et al. (1999)

Hyperforin

0.1-1.0 µg/ml

No inhibition

Yesilada et al. (1999)

BuOH, CHCl3

7.8-250 µg extract/ml

Not assayed

Reichling et al. (2001)

Boiling H2O extract

1.3-30 mg herb/ml

15-60 or >60 mg
herb/ml

Avato et al. (2004)

CHCl3, EtOAc, MeOH, Pet.
Ether

25-300 or >1000 µg
extract/ml

No inhibition

Hyperforin, Hyperforin salt

25-100 µg/ml

No inhibition

Hypericin

12.5-25 or >1000µg/ml

No inhibition

Flavonoids

>1000 µg/ml

No inhibition

EtOH

3.5 mg extract/ml

1.25-3.5 mg
extract/ml

Neuwald & Hagenstrom
(1954)

Milosevic & Solujic
(2006)
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Table 2.2 A comprehensive list of all organisms assayed in cited SJW inhibitory assays,
showing Gram-positive strains (left column), Gram-negative strains (center column), and
yeasts (right column). Corresponding authors of studies are shown in bottom right of
table.
Gram-Positives
Bacillus cereus

Gram-Negatives
i

Agrobacterium tumefaciens

Bacillus mycoides
Bacillus subtilis

d,j

c,d,i,j
c,f

Corynebacterium michiganense
Enterococcus faecalis

d

d,f,h,i

Listeria monocytogenes

h

Sarcina lutea

h

Cryptococcus laurentii

Enterobacter aerogenes

a,b,c,d,e,f,h,i

Staphylococcus epidermidis

h

Staphylococcus saprophyticus
Streptococcus agalactiae

f

Streptococcus haemolyticus
Streptococcus mutans

e

Streptococcus pyogenes
Streptococcus sanguis
Streptococcus viridans

e
c

f,h

Fusarium oxysporum

j

d

Penicillium canescens
h,j

d

j

Saccharomyces cerevisiae

i

h

e

Proteus vulgaris

j

Author(s) (Year)

j

a. Osborn (1943)

Pseudomonas phaseolicola
Pseudomonas aeruginosa

c

d

i

Penicillium chrysogenum

g

Pseudomonas glycinea
h

i

Fusarium avenaceum
Mucor plumbeus

Pseudomonas fluorescens

e

Staphylococcus oxford

j

a,b,c,e,f,h

Proteus mirabilis

Staphylococcus aureus

h

j

Klebsiella pneumoniae

d

d,f,h,i

Citrobacter freundii

Helicobacter pylori
c

Candida albicans

Candida tropicalis

Escherichia coli

Mycobacterium tuberculosis

i

c

Erwinia carotovora

d

Aspergillus niger

Bacillus pyocyaneus

Enterobacter cloacae

h

Mycobacterium phlei

j

Azotobacter chrococcum

Corynebacterium diphtheriae

MRSA

Yeasts
j

j

e,f,h

b. Neuwald & Hagenstrom (1954)
c. Gaind & Ganjoo (1959)

Salmonella choleraesuis

h

d. Gurevich et al. (1971)

Salmonella paratyphi A

c

e. Barbagallo & Chisari (1987)

Salmonella paratyphi B

c

f. Schempp et al. (1999)

b,c

Salmonella typhi

Shigella dysenteriae
Shigella flexneri
Vibrio cholerae

h

c

g. Yesilada et al. (1999)
c

h. Reichling et al. (2001)
i. Avato et al. (2004)
j. Milosevic & Solujic (2006)
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Figure 2.1 Chemical structures of Hpn (a), Phn (b), and Hfn (c) (Bauer et al., 2001).
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CHAPTER 3
HPLC-DAD QUANTIFICATION OF SJW COMPOUNDS
Introduction
Compounds in the SJW herb are of interest to the medical community for their
antidepressant, antibiotic, anticancer, antiviral, and anti-inflammatory activity. A simple
high-performance liquid chromatography (HPLC) method was developed during the
course of these studies that uses common HPLC separation and analysis equipment for
the quantification of pseudohypericin (Phn), hyperforin (Hfn), and hypericin (Hpn). This
30-min method requires only two mobile phases, a multi-wavelength UV/VIS detector
(such as photodiode array), and a C18 column. The concentrations of the three
compounds in the methanol (MeOH) SJW extract were determined. This method is
particularly useful for laboratories that do not have the more expensive equipment called
for by many SJW HPLC analytical protocols.
Materials and Methods
Acidified MeOH Preparation
Acidified MeOH, pH 2.5, was prepared using 85% phosphoric acid (H3PO4,
Mallinckrodt Chemicals, Phillipsburg, NJ) (de los Reyes and Koda, 2001). The pH was
lowered dropwise with a 9” glass Pasteur pipette (Fisherbrand, Fisher, Pittsburgh, PA).
Previously, volume dispensation of this pipette was measured using a laboratory balance
and dividing the average mass of 30 drops of acid by its density (1.685 g/ml for 85%
H3PO4) to obtain an average of 17.98 µL of 85% H3PO4 per drop. A glass pH probe
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calibrated using aqueous buffers was used to determine that 11 drops per 250 ml MeOH
(Fisher Chemicals, Pittsburgh, PA), or a solution of 0.079% (v/v) H3PO4, brought the
measured pH to 2.5. Oxygen was then removed by sparging with nitrogen for
approximately 10 min. Evaporation was minimized by capping the bottle with Parafilm
that had a small puncture for gas escape.
SJW Crude Extract and Pure Compound
Preparation
SJW crude extract preparations were performed in low-intensity green filteredlight using a headlamp (Quad Tactical LED, Princeton Tec, Trenton, NJ) with
wavelength emissions above the degradation ranges (400 nm) (Figure 3.1). Hfn, Hpn,
and Phn standards (Enzo Life Sciences, Plymouth Meeting, PA) were brought to
concentrations of 4000 µg/ml by adding acidified MeOH with syringes. These were
stored in 1-ml amber glass crimp vials (Fisherbrand, Fisher, Pittsburgh, PA) at -20˚C.
SJW powder used for making the crude extract was prepared by grinding the
contents of SJW capsules (GNC, Pittsburgh, PA) to a fine powder using a mortar and
pestle and storing at 4˚C. A “1X” MeOH extract was prepared by adding 30 ml acidified
MeOH to 10.8 g SJW powder in a 50-ml centrifuge tube (Corning, Corning, NY). A
“2X” extract was similarly prepared by adding 15 ml acidified MeOH to 10.8 g SJW
powder. The contents were mixed by vortexing and shaking and stored at room
temperature overnight. After vortexing and shaking again the next day, the mixtures
were centrifuged for 10 min at 4000 RPM (3452 RCF). The supernatant was 0.2-µm
filtered and stored in a 10-ml amber glass vial at -20˚C.
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Determination of Herb Volume, Porosity,
and Extract Concentrations
Specific herb volume was determined by adding 30 ml acidified MeOH to 10.8 g
of SJW powder, mixing thoroughly, and dividing the volume increase by herb mass.
Porosity was determined using equation 1. The void volume (VV) was the difference of
the dry herb volume (VT) and the true (wet) volume.

Porosity =

VV
VT

(1)

Extract masses of the 2X and 1X SJW solutions were determined by measuring the dry

€ (in triplicate) of these extracts. This was done by subtracting the
weight of 1-ml
premeasured mass of the weigh boats from the oven-dried (60ºC) extracts after two days
and averaging the triplicate for each extract. Using a scale, it was determined that a 1-ml
syringe (BD, Franklin Lakes, NJ) was more accurate for dispensing this organic solution
than a pipette with plastic tip, even after wetting the tip.
SJW Solubility Testing
Preliminary HPLC work revealed problems with precipitation of organic SJW
extract in the mobile phase, causing clogging of the pre-column. Therefore, a solubility
test was devised to determine the solubility ranges of SJW MeOH extract in the common
HPLC solvents MeOH and acetonitrile (ACN) (Honeywell Burdick & Jackson, West
Chester, PA). Aqueous concentrations of these solvents were prepared from 0-100%
(v/v) in 10% increments. 1X SJW MeOH extract was then added at a 2% (v/v)
concentration. Optical density measurements at 600 nm (OD600) were taken to determine
maximum solubility ranges of SJW MeOH extract in these solvents.
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HPLC Analysis
Mobile Phase Preparation. Mobile phase A was 80:20 acetonitrile:water and
0.035% (v/v) 85% H3PO4. Mobile phase B was 99:1 acetonitrile:water and 0.035% (v/v)
85% H3PO4. Degassing was performed using a Fisher Scientific sonicator (FS60, Fisher,
Pittsburgh, PA) for 45 min, with bottles wrapped in Parafilm punctured with small holes
to allow gas escape.
Line and Pump Priming. Line and pump priming was achieved by pulling 10 ml
through the tubing, discarding, then pulling another 10 ml through the tubing and using
this to prime each respective pump. The detector and pumps were run for 10 min (with
the pumps at 50:50 A:B at 0.5 ml/min), after which a blank run was performed to clean
the column and run the pumps at higher flow rates.
HPLC Method. The HPLC instrument used was a Beckman System Gold model
125S equipped with a 168 photodiode array (or simply “diode array”) detector (DAD).
Injection volume was 60 µl into a 20 µl loop to compensate for laminar flow issues and
done at a rate of approximately 5 µl/s. To prevent column overloading when analyzing
the crude extract, a 1:50 dilution (2% v/v) was used (this volume was also used most
commonly in the SJW inhibitory studies). The HPLC method was as follows: at 0 min
100:0 A:B at 1.5 ml/min; at 8 min a 0.5-min flow rate increase to 2.5 ml/min; at 11 min a
0.5-min flow rate decrease to 1.5 ml/min and a 1-min A-B gradient to 0:100 A:B; at 16
min a 0.5-min flow rate increase to 2.5 ml/min; and at 28 min a 0.5-min flow rate
decrease to 1.5 ml/min and a 1-min B-A gradient to100:0 A:B to equilibrate the column
in preparation for the next run. The method ended at 30 min.
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Loop and Injector Cleaning. Loop and injector cleanings between runs were done
by flushing 1 ml of mobile phase A using a 1-ml blunt-end syringe with a Parafilm
wrapping around the needle to allow for sealing against the injection port. Some cleaning
solution was allowed to flow backwards out from the port to clean the port entrance.
Sample injection syringe cleaning was done using several (usually three) EtOH rinses
followed by several acidified MeOH rinses.
Peak Analysis and Preparation of Calibration Curves. Analysis of peak area was
performed using the Gold Noveau integration software with absorbance readings taken at
the following wavelengths: Phn: 590 nm; Hfn: 273 nm; Hpn: 578 nm. Threshold and
peak width settings had to be changed from time to time, especially for the hypericins, to
cause the peak integration baseline to span the bottom of the peak.
Calibration curves were prepared through selection of the most accurate and
precise of three calibration curves prepared for each of the three active compounds. The
calibration curves for Phn and Hpn consisted of five points (as these were more difficult
to quantify) in singlet, while the calibration curve for Hfn consisted of four points in
duplicate. Final Phn and Hpn calibration curves spanned concentrations from 12.5-100
µg/ml, and the final Hfn calibration curve spanned concentrations from 5-100 µg/ml.
The three compounds were usually mixed together and analyzed simultaneously,
allowing for more efficient calibration curve preparation. Acidified MeOH was the
diluent used to prepare the solutions.
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Repeatability Testing
Three sets of calibration curves allowed for the investigation of the repeatability
of this method. Repeatability was determined by investigating the variation between sets
of regression equations for each compound, given a certain area.
Determination of Active Compound
Photoconversion or Photodegradation
Photoconversion/photodegradation of SJW compounds were investigated by
preparing a fresh 10-ml amber glass vial of 1X SJW extract and placing it in a New
Brunswick Scientific Innova 42 photosynthetic incubator-shaker, shaking approximately
5 cm beneath the photosynthetic light at a photon irradiance of 223 µmole/m2/s/nm. The
spectrum and light intensity of this incubator are shown in Figures 3.2 and 3.3,
respectively, with the spectrum almost completely above 400 nm. Samples (250 µl each)
were taken from the vial at times 0, 15 min, 30 min, 1 hr, and 2 hr, and active compound
concentrations were analyzed using the regression equations from the calibration curves.
Results and Discussion
Herb Volume, Porosity, and
Extract Concentrations
Wet (true) and dry volumes and porosity of the ground SJW herb, as well as
concentrations of the extract, are given in Table 3.1. It can be seen from these values that
the MeOH dissolved a substantial part of the herbal mass (46.1% for 1X and 46.5% for
2X). Hence, about 46% of the herb mass is soluble in MeOH using the extract
preparation methods outlined above. Though the MeOH volume added for the 1X
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solution was twice the volume as the MeOH added for the 2X solution, to the same mass
of SJW herb, this did not double the 1X solution volume (as the herb itself occupies
considerable volume at these concentrations). The 1X solution had a 67% higher volume
than the 2X solution. The 2X extract had approximately the same percentage greater
measured mass (68%) than the 1X extract. If the 2X extract had been saturated, its
percentage mass increase (compared to 1X) would have been less than the percentage
volume increase of 1X. Therefore, these results show that the 2X extract had not reached
the solubility limit of SJW in MeOH. The extracts were observed qualitatively to have a
high viscosity and a dark, tar-like appearance, even after filtering through a 0.22 µm
filter.
SJW Solubility
The OD600 data for SJW MeOH extract solubility in MeOH and ACN is shown in
Figure 3.4. Greatest solubility was found to be at values greater than 70% MeOH or
between 60-80% ACN. It was found that if the beginning mobile phase was outside of
the SJW solubility range, it caused analyte precipitation and clogging in the pre-column.
Therefore, the “A” mobile phase of 80% ACN(aq) was found to be effective at quickly
eluting the non-targeted polar compounds. By using this mobile phase isocratically for
the first 10 min of the run, it also provided clear resolution of compounds through the
elution of Phn. Afterward, there was no precipitation as the gradient moved to 99%
ACN.
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Chromatograms, HPLC Parameters, and
Standard Curves
Typical chromatograms for the Phn, Hfn, and Hpn standards are shown in Figure
3.5, and their corresponding crude extract chromatograms are given in Figure 3.6.
Calibration curves for these compounds are shown in Figure 3.7. Retention time ranges,
regression equations from the calibration curves, and correlation coefficients are shown
in Table 3.2. Compound concentrations in a 1:50 dilution of the 1X extract are shown in
Table 3.3. It should be noted that as the concentrations of the hypericins increased, the
retention times decreased; therefore, there were small time ranges for the retention times
of these compounds. Also, though formal limit of detection (LOD) tests were not
performed, the hypericins were generally difficult to detect at concentrations lower than
25 µg/ml. Hfn was easily detectable at all concentrations attempted. The lowest
attempted concentration of Hfn was 1 µg/ml, which produced a sharp, easily integratable
peak, so lower concentrations of this analyte should also be integratable. Figure 3.8
shows a contour view of the DAD data for a typical crude extract HPLC run, with X-axis
time, Y-axis wavelength, and Z-axis (coming toward the viewer) milli-arbitrary (or
absorbance) units (mAU), which has magnitude marked by color. Magnitude color
indicators (from highest to lowest) are red, yellow, green, light blue, dark blue, and
purple. Analysis was performed at 590 nm for Phn, 273 nm for Hfn, and 578 nm for
Hpn. This view shows the numerous compounds in SJW that are able to be effectively
resolved using this HPLC method.
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Repeatability
This method was found to be highly repeatable for Hfn and less repeatable for
Phn and Hpn, as shown in the compound concentration values from each calibration
curve, along with their means and standard deviations, in Table 3.3. As the standards
used in the creation of both the method and the first set of calibration curves were
somewhat old (six weeks) and returned relatively imprecise values for the hypericins, it
was decided to not make the first set the official calibration curves for this method.
The second and third calibration curve regression equations for Phn and Hfn
returned concentration values within 2% of each other. It was decided to use the
regression equation from third calibration curve for Hfn, as the four points in this
calibration curve came from duplicate analysis using fresh stock solution. The regression
equations from the second set of standard curves were used for the hypericins; even
though these calibration curves were performed in singlet, they each consisted of five
points (as opposed to three points in the third set due to difficulty in integrating
concentrations below 25 µg/ml), produced higher correlation coefficients, and were
prepared with fresh stock solution. The Hpn calibration curve used successfully
integrated peaks at 5 µg/ml and 10 µg /ml, which was another reason it was used.
Photoconversion/Photodegradation
of Active Compounds
Normalized concentration data for the three SJW analytes after exposure to the
Innova photosynthetic light are shown in Figure 3.9. There was a 20% increase in Phn, a
4% decrease in Hpn, and a 41% decrease in Hfn. The loss in Hfn was considered to not
be worth the relatively small photoconversion-gain in Phn, so photoconversion was not
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carried out in any additional experiments. These novel results show degradation of Hfn
at wavelengths above 400 nm, contrary to reported values on the subject (Ruckert et al.,
2007).
Discussion
As the use of MeOH in HPLC analysis is often preferred due to its relatively low
cost, several attempts were made to use this solvent in our analysis. However, this
solvent did not have the hydrophobicity necessary to elute the highly nonpolar Hpn
within the target 30-min timeframe. Also, the primary purpose of this HPLC method is
for efficient analysis, not preparative purposes, and does not use an exorbitant amount of
solvent. Therefore, the benefits outweigh the drawbacks in the use of ACN along with
MeOH.
The development of a 30-min SJW HPLC quantification method with a C18
column for Phn, Hfn, and Hpn proved to be a difficult task. This was primarily due to the
chemical properties of the hypericins, which caused relatively wide peak bases, tailing,
and in the case of Hpn, a long retention time. To narrow the Phn and Hpn peaks in this
method, flow rates were increased from 1.5 ml/min to 2.5 ml/min during the elution of
both of these peaks. Though less hydrophobic columns, such as a C8 or C12 column, are
able to provide a sharper peak shape for the hypericins, the C18 column is more common,
and that is why this method was developed. However, the less hydrophobic column is
recommended if available, in which case a different method would have to be used (such
as that outlined by Ganzera et al., 2002).
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It was also determined that injecting three times the sample loop volume helped to
overcome laminar flow issues and purge the mobile phase from the loop, thereby
injecting a pure 20 µl of sample into the column. It was found that this allowed for
greater consistency in peak area, as shown by the relatively high correlation coefficients.
It was also found that if there was not enough analyte volume to inject three times the
loop volume, a very slow injection of a smaller volume could also achieve consistency.
The last part of the HPLC method goes through an equilibration phase to prepare
the column for the next run, which can be started immediately should the need exist.
After preparing this method initially, the HPLC run time was allowed to go far beyond 30
min to ensure that Hpn was the last SJW compound to exit the column, which it was.
Therefore, this method allows for the user to immediately begin another run.
Conclusions
A SJW HPLC method for the quantification of Phn, Hfn, and Hpn within 30 min
has been developed and shown to be effective. This method requires only two mobile
phases, a UV/VIS detector (such as photodiode array), and a C18 column. It also avoids
clogging of the extract in the precolumn. While this method may be used for the
quantification of Phn and Hpn, it is most accurate and repeatable for the quantification of
Hfn. It has been found that wide Phn and Hpn peaks is a common problem in C18
column analysis of SJW, and for increased accuracy in their analysis, a method utilizing a
less hydrophobic column is recommended. The biggest advantage of our method is for
researchers who are interested in investigating SJW who only have access to the most
common HPLC separation and detection equipment.
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Table 3.1 Volumes, concentrations, and porosity of SJW herb and MeOH extract. Only
the 2X and 1X extracts were assayed using HPLC. The other dilutions are dilutions of
the 1X extract and are listed for reference for other chapters (usually added to cultures at
1:50 dilutions). SJW extract concentration is mg solids, not solution, per ml.
SJW	
  Herb	
  
Ground	
  Herb	
  
SJW	
  Extract	
  
2X	
  
1X	
  
1/2X	
  
1/4X	
  
1/8X	
  
1/16X	
  

Wet	
  volume	
  (ml/g)	
  
0.694	
  
mg	
  herb/ml	
  solvent	
  
720	
  
360	
  
180	
  
90	
  
45	
  
23	
  

Dry	
  volume	
  (ml/g)	
  
1.39	
  
mg	
  herb/ml	
  solution	
  
480	
  
288	
  
144	
  
72	
  
36	
  
18	
  

Porosity	
  
0.501	
  
mg	
  extract/ml	
  solution	
  
223	
  
133	
  
67	
  
33	
  
17	
  
8	
  

	
  
	
  
Table 3.2 Retention times, regression equations, and correlation coefficients (R2) for the
three SJW analytes from 1:50 dilutions of SJW extract. The regression equations came
from the second set of calibration curves for Phn and Hpn and from the third set for Hfn.
Parameter	
  
Retention	
  time	
  
Regression	
  equation	
  
Correlation	
  coefficient	
  

Pseudohypericin	
  
10-‐10.5	
  min	
  
Y=1419.9x-‐3739	
  
0.996	
  

Hyperforin	
  
15	
  min	
  
Y=10553x-‐1063.2	
  
0.999	
  

Hypericin	
  
22.5-‐23.5	
  min	
  
Y=5100.1X-‐6667.2	
  
0.995	
  

Table 3.3 Assayed concentration values of SJW compounds at 1:50 dilution of the 1X
crude extract. Three sets of calibration curves were prepared for Phn and Hfn, and two
were prepared for Hpn to test repeatability. The second sets of calibration curves were
used for Phn and Hpn, and the third set was used for Hfn. Compound concentrations are
listed at this dilution for ease in comparison with the inhibitory studies in Chapters 4 and
5, as this is the most common concentration (v/v) that the crude extract was added to
cultures.
Cal.	
  Curve	
  Set	
  
1	
  
2	
  
3	
  
Mean	
  
Std.	
  Deviation	
  
	
  

Pseudohypericin	
  (µg/ml)	
  
34.4	
  
53.4	
  
54.4	
  
47.4	
  
11.3	
  

Hyperforin	
  (µg/ml)	
  
43.3	
  
46.2	
  
45.5	
  
45	
  
1.5	
  

Hypericin	
  (µg/ml)	
  
26.4	
  
15.4	
  
NA	
  
20.9	
  
7.8	
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Figure 3.1 Normalized spectra of filtered-light headlamp used when working with lightsensitive compounds. The green filter was mostly used, as its emission corresponded with
the photoconversion (from their protoforms) wavelengths of the hypericins (510-540 nm)
and prevented Hfn degradation, which occurs below 400 nm (Poutaraud et al., 2001b).
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Figure 3.2 Spectrogram of the Innova incubator-shaker photosynthetic light. Very little
emission is seen below 400 nm (Hfn-damaging wavelengths).
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Figure 3.3 Photon irradiance of the Innova incubator-shaker photosynthetic light as a
function of distance from the light source. The photoconversion/photodegradation
experiment was carried out at a distance of 5 cm with a photon irradiance of
223 µmol/m2/s/nm.
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Figure 3.4 Solubility (OD600) of 2% (v/v) SJW crude MeOH extract in various aqueous
concentrations of MeOH and ACN. Lower OD equals higher solubility. The crude
extract had highest solubility at concentrations of ≥ 70% MeOH or 60-80% ACN.
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Figure 3.5 Typical chromatograms for Phn, Hfn, and Hpn standards, with retention
times of approximately 10, 15, and 22.5 min, respectively. The 273 nm chromatogram
for Hfn is below (blue), and the 590 nm chromatogram for the hypericins is above (red).
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Figure 3.6 Typical chromatograms for Phn, Hfn, and Hpn in 1:50 dilution of 1X (2.66
mg extract/ml) crude extract, with retention times of approximately 10.5, 15, and 23.5
min, respectively. The 273 nm chromatogram for Hfn is below (blue), and the 590 nm
chromatogram for the hypericins is above (red).
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Figure 3.7 Calibration curves used in the quantification of SJW compounds. The Hfn
curve had the highest correlation coefficient, followed by Phn, then by Hpn. The Hfn
calibration curve shown was the third curve prepared for this compound, and the
hypericins were each their second calibration curves prepared.

Hyperforin
(273 nm)

Pseudohypericin
(590 nm)

Hypericin
(578 nm)

Figure 3.8 Contour view of HPLC mAU data for SJW crude extract. X-axis is time
(min), Y-axis is wavelength (nm), and Z-axis (coming toward the viewer) is absorbance
(mAU). Red represents highest absorbance, followed by yellow, green, light blue, dark
blue, and purple.

40
#

"

$ %

Figure 3.9 Photoconversion/photodegradation study of SJW compounds. A 20%
concentration increase was observed in Phn, a negligible concentration change was
observed in Hpn, and a 40% concentration decrease was observed in Hfn. While Ruckert
et al. (2007) state that Hfn degradation occurs at wavelengths below 400 nm, these
findings show significant Hfn degradation above 400 nm.
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CHAPTER 4
EFFECT OF HYPERICUM PERFORATUM ON MYCOBACTERIA VIABILITY
Introduction
Of all the literature reviewed, only two Mycobacterium strains, one time each,
have been included in SJW inhibitory/bactericidal assays. This is an insufficient sample
size if one is to understand the response of this genus to SJW extracts and compounds.
To create a larger data set on the response of mycobacteria to SJW, seven nonpathogenic
mycobacteria (six of which are the only genetically sequenced nonpathogenic
Mycobacterium strains currently available) were used in a series of inhibitory and
bactericidal studies presented here. These strains contain as much as 72% homology to
the M. tuberculosis genome (see Figure 4.1 for a Venn diagram comparison of these
genomes). With these results, investigators should be able to better predict how
pathogenic mycobacteria might respond to the SJW herb.
Materials and Methods
Comparison of Mycobacterial Genomes
Mycobacterial genomes were compared using the Integrated Microbial Genomes
(IMG) section of the Department of Energy (DOE) Joint Genome Institute (JGI) website
(www.jgi.doe.gov). Under the menus “Find Genes,” “Phylogenetic Profilers,” “Single
Genes,” the “Find Genes In” option was selected for M. gilvum PYR-GCK, and the
“With Homologs In” option was selected for all nonpathogenic Mycobacterium isolates
and for M. tuberculosis CDC1551. Similarity cutoffs were as follows: Max. E-value: 1e-
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5, Min. Percent Identity: 30, Exclude Pseudo Genes: No, Algorithm: By Present/Absent
Homologs, Min. Taxon Percent With Homologs: 100, Min. Taxon Percent Without
Homologs: 100.
SJW Extract and Pure Compound
Preparation
SJW extracts and pure compound solutions were prepared in the manner outlined
in Chapter 3. The solvent used for preparing SJW extracts in most of the inhibitory
studies was MeOH. However, acetone, ethanol, ethyl acetate, chloroform, and water
were also used for a study comparing the inhibition of SJW extracts of different solvents.
SJW from GNC (Pittsburgh, PA) was used for most studies. However, the Nature’s Way
(Springville, UT) and NOW (Bloomingdale, IL) brands of SJW were also used in a study
comparing SJW brands. Extracts used in the earliest studies were not 0.2-µm filtered, but
nearly all studies used filtered extract. Dilutions of the crude extract were made by
diluting the 1X, not 2X, stock solution (Table 3.1).
Media Preparation
Luria broth (LB) and agar, as well as Middlebrook broth (MB) and agar, were
prepared according to protocols in the Appendix. Ampicillin was added to the media for
one study comparing growth with and without it and was added from stock solution to a
working concentration of 50 µg/ml. Tween 80 (Sigma, St. Louis, MO) was often added
at a 0.5% (v/v) concentration of a 10% (w/v) stock solution, making a working
concentration of 0.05%.
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Culture Preparation
Cultures and Growth Conditions Used. The Mycobacterium cultures used for the
inhibitory/bactericidal studies were M. JLS, M. KMS, and M. MCS (isolates from Utah
State University), M. smegmatis (#14468, ATCC, Manassas, VA), M. phlei (ATCC
#BAA-486), and M. vanbaalenii PYR-1 and M. gilvum PYR-GCK (isolates obtained
through a combined Joint Genome Institute sequencing effort). Gram-negative controls
were Pseudomonas putida (obtained on USU campus) and Escherichia coli (ATCC
#25922). The Gram-positive control was Bacillus subtilis (ATCC #6051). A qualitative
study was performed that compared the growth of mycobacteria on LB and MB media,
and LB media was used for all other studies. All cultures were incubated at 37°C except
for B. subtilis, which was incubated at 30°C. Broth cultures were incubated in shaking
conditions at 220 RPM for 12-ml culture tubes (BD Falcon, Franklin Lakes, NJ) or 150
RPM for 48-well plates (BD Falcon, Franklin Lakes, NJ).
Freezer Stock Preparation. Freezer stocks of the bacterial isolates were prepared
by adding 500 µl of turbid culture to 500 µl of 30% (v/v)(aq) sterile glycerol, bringing the
final cell solution to 15% (v/v) glycerol, in a 1.5 ml microcentrifuge tube (Fisher,
Pittsburgh, PA). This was kept at -80ºC.
Broth Culture Preparation. Broth cultures were inoculated by adding a volume
of bacterial freezer stock (typically between 50-200 µl, with more volume for shorter
time to turbidity) to liquid media. Inoculations were typically done in 5 ml media in 12ml culture tubes. At the beginning of experiments, cultures were diluted with LB media
in a 50-ml centrifuge tube (Corning, Corning, NY) (typically about a 1:100 dilution) to an
optical density (OD600) of between 0.01-0.05 using a spectrophotometer (Bio-Spec Mini
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00834, Shimadzu, Columbia, MD). If Tween 80 was to be added, it was also done at this
time prior to dispensing the inoculated media into the assay containers, which were either
12-ml culture tubes or 48-well plates.
Agar Plate Culture Preparation. Agar plate cultures were prepared either for
working culture storage or for SJW inhibitory assays. For streak plates, a small amount
of bacteria was streaked in small portion of the plate along the edge (about 1/5 of the
plate). This first section required either a small volume (5-10 µl) of liquid culture or a
small amount (barely visible on a pipette tip) of bacteria from another plate. Using a
pipette tip (usually a 1.5-ml tip), this section of the plate was then streaked over to the
next 1/5 of the plate using a new tip. This process was repeated, each time using a new
tip, until all sections of the plate had been streaked. If several strains were used on one
plate, then the plate was divided into sections, and each strain was streaked only in its
section.
Culture Treatment
Inhibitory Assays. Inhibitory assays (not bactericidal assays) were performed on
SJW-containing agar plates. These studies used plates that had SJW crude extract or
solvent (for controls) added to the plates at their coolest point before solidification. The
plates were then swirled to mix and allowed to solidify before treating with cultures.
Crude extract was added at equal concentrations for a study comparing inhibition of three
different SJW brands and extracts of six different solvents, and it was added at different
various concentrations for a study investigating MIC values. Plates with no growth were
above the minimal inhibitory concentration (MIC), and plates with growth were below it.
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When pipetting SJW crude extract solution or organic solvents, greater accuracy was
achieved by “wetting” the tip, pipetting up and down once or twice before the final
aspiration and dispensing. Pipetting accuracy was measured using a laboratory scale to
verify accurate weight using the solvent density.
Bactericidal Assays. Bactericidal assays were performed in SJW-containing broth
media. After culture preparation, SJW crude extract or pure compounds were added to
the cultures at various concentrations in low-intensity green-filtered-light conditions.
Crude extract studies were carried out in culture tubes (except when used for comparison
in the pure compounds MBC studies, in which case a 48-well plate was used), while pure
compound studies were carried out in 48-well plates (except for one study comparing the
effect of light exposure on Hfn inhibition of M. KMS, in which case 12-ml culture tubes
were used). For accurate dispensing of volumes, syringes were used to dispense the SJW
treatments. For volumes between 250-1000 µl, a 1-ml graduated syringe (BD, Franklin
Lakes, NJ) was used. For volumes less than 250 µl, graduated glass syringes were used
(Hamilton, Reno, NV). After EtOH/MeOH toxicity studies, SJW crude extract and pure
compounds were added at concentrations at or below 2% (v/v). Cultures were then kept
at the appropriate temperature (stated above), and cell samples were taken at various time
points for cell counting (method outlined below).
Effect of Tween 80 on Hfn MBC Study. A study investigating the effect of various
concentrations of Tween 80 on Hfn MBC was performed using M. JLS as a
mycobacterial representative. Cultures containing six concentrations of Tween 80 (2-fold
dilutions) were added to a 48-well plate in triplicate and all treated with the same Hfn
concentration of 46 µg/ml. A no-Tween 80 control, as well as a no-Tween 80/Hfn
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control, were included. CFU counts were taken each day for 3 days, with the first CFU
count taken before Hfn addition.
Colony Forming Unit (CFU) QuantificationCell Dilution Method
The cell dilution method was by performed by doing the following: in a 96-well
Costar plate (Fisher, Pittsburgh, PA), 90 µl of LB media was placed in columns 2-8 using
an Eppendorf eight-channel pipette (Fisher, Pittsburgh, PA) with Eppendorf ep tips
(Fisher, Pittsburgh, PA). After thoroughly resuspending a cell culture using a larger
pipette, 30 µl were taken and placed into a well in column 1. After column 1 had been
filled with samples from eight cultures, the multichannel pipette was used to perform
serial dilutions, changing tips between each column. Minor but important techniques
included the following: (1) ensuring a tight fit of the pipette tips on the pipette; (2)
thoroughly mixing the contents of the wells in each column before transferring to the next
column (via stirring and pipetting up and down several times with the pipette tips); (3)
keeping the tips off the bottom of the wells to avoid sudden aspiration (which leads to
excessive volumes); and (4) visually inspecting the tips for precision and to ensure the
presence of solution in the tips before transferring to the next column.
Each cell dilution was spotted on an antibiotic-free LB agar plate. Blowing out
with the pipette when applying spots to a plate was avoided due to spraying when the
bubble in the spot burst, which would cause rogue colonies and less-accurate CFU
counts. Instead, pipette volume was adjusted to slightly higher (0.5 µl higher) than
desired dispensing volume (10 µl) to compensate for the volume not dispensed from not
blowing out. After securing four pipette tips on the pipette, the four most dilute wells in
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a row of the 96-well plate were thoroughly mixed, and four spots were placed on the
plate. Uniform spots were obtained by slowly dispensing the liquid (forming droplets on
the tips) and slowly lowering the drops to the surface (touching the media with the tips
was avoided, as spraying could occur with pressure build-up if the tip was touching the
agar). Without changing tips, the four most concentrated wells in the same row were
then thoroughly mixed and placed on the agar plate in the same manner. The plates were
allowed to sit in the laminar flow hood until the spots absorbed into the media (about 3045 min), after which they were wrapped in Parafilm and placed in an incubator (37ºC for
all strains except for B. subtilis and E. coli, which were incubated at room temperature
due to their higher growth rates).
After visual colony growth on the plates (about four to five days for mycobacteria
and one day for E. coli and B. subtilis), colonies were counted. Two counts were taken
from the two spots that had the highest number of countable colonies. These values were
then back-calculated to yield CFU/10 µl, then multiplied by 100 to yield CFU/ml. The
two CFU counts from each plate were averaged as the final CFU count, with the error
being the standard deviation. A “time 0” count was always taken, usually before the
addition of SJW crude extract or compounds, followed by additional counts at various
time points.
Scanning Electron Microscopy (SEM) Cell
Fixing
Scanning electron microscopy (SEM) imaging was performed for all the strains
without SJW treatment, and imaging was performed for M. KMS, M. smegmatis, B.
subtilis, and E. coli after treatment with the crude extract at various concentrations and
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time points. Cell fixation and imaging procedures were performed by Dr. TC Shen and
Dr. FenAnn Shen of the USU Physics Department. Cell fixation protocols are in the
Appendix.
Results and Discussion
Comparison of Mycobacterial Genomes
Homology comparisons of all nonpathogenic Mycobacterium genomes with M.
tuberculosis are shown as a Venn diagram in Figure 4.1. The outer, non-percentage
numbers indicate number of genes. The outer percentages indicate percent genes unique
to each isolate. Middle percentages indicate percent genes shared with M. tuberculosis.
Inner percentages indicate percent genes of M. tuberculosis that are incorporated into
each isolate, which is of greatest interest for this study. Percent M. tuberculosis genome
incorporation is as follows (from greatest to least): M. MCS (72%), M. smegmatis (69%),
M. KMS (69%), M. vanbaalenii (67%), M. JLS (66%), and M. gilvum (65%). This
comparison sheds greater light on the selection of organism for a M. tuberculosis
surrogate. M. smegmatis is commonly used as a pathogenic surrogate, but for
tuberculosis studies, perhaps M. MCS would be a more appropriate choice, with three
percentage points greater similarity. M. MCS was found to have the greatest morphology
similarity to M. smegmatis out of all assayed isolates from these studies; colonies from
these isolates were found to grow more laterally and have a more “dry” appearance on an
agar plate than other isolates, and there was a higher degree of cell clumping in liquid
culture than other isolates. The high degree of clumping of these two isolates did make
CFU quantitation difficult, however. Therefore, isolates that exhibited less clumping,
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such as M. JLS or M. KMS, were often chosen to act as mycobacterial representatives in
studies requiring many samples that could only accommodate one or two strains. The
isolates assayed the most through these studies are shown in Figure 4.2: M. JLS, M.
KMS, M. MCS, M. smegmatis, and M. phlei.
Demonstration of Inhibitory Effect of
Extracts of Different Solvents and
Different SJW Brands
The inhibition/growth results of M. JLS, M. KMS, M. MCS, M. vanbaalenii, M.
gilvum, and Gram-negative-control Pseudomonas putida control after one week and two
weeks are shown in Tables 4.1 and 4.2, respectively. Plates where fungal contamination
occurred (as this study did not use filtered crude extract) are denoted as “not determined”
(ND). Growth inhibition occurred in all organic extracts of SJW, with the exception of
the Nature’s Way chloroform extract; plates with this SJW brand showed growth of M.
gilvum PYR-GCK in the ethyl acetate plate and growth of all strains except M.
vanbaalenii PYR-1 in the chloroform plate. The cause for this is uncertain, though
settling of the relatively high-density chloroform (specific gravity 1.48) may have had an
effect. No inhibition occurred in any plates containing water SJW extract except the
GNC M. MCS plate. The results show very little differences between the different brands
of SJW and between different types of organic extracts. As GNC SJW was easy to obtain
and showed the least amount of fungal contamination, and since MeOH was the most
commonly used solvent in other SJW studies in literature, GNC SJW and MeOH were
used for the remaining studies. Images of the GNC plates for each type of solvent, along
with the controls, are shown in Figure 4.3.
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It is interesting to note the pigmentation differences between the extracts of the
various solvents. The dark pigmentation caused problems in colorimetric assays
throughout the study (i.e., spectrophotometric growth assessment or protein assay). The
ethyl acetate extract was much less pigmented in media than the others yet still inhibited
mycobacterial growth. Hence, future studies may warrant the use of the ethyl acetate
extract and LB media to reduce pigmentation and make colorimetric/spectrophotometric
assays a more viable option.
Comparison of Mycobacterial Growth on
Different Media Types
While no significant difference was seen in cell growth on LB or MB media, there
was significant difference seen in cell pigmentation, particularly in the USU isolates M.
JLS, M. KMS, and M. MCS (Figure 4.4). The LB plates produced cells with a deeper
yellow pigmentation, making them easier to see. Due to the easier visibility of the cells
on LB, the relative ease of making this media, and its lower cost, it was decided to use
LB media for the remainder of this study.
Ampicillin Resistance of Mycobacteria
The effect of ampicillin (50 µg/ml) on the growth of the five mycobacterial
isolates is shown in Figure 4.5. While there was not a dramatic visual difference in cell
growth, the ampicillin did have an effect on cell pigmentation; the cause for this is
unknown. As cell visibility was a necessity for this study (for CFU counting), antibiotics
were not used in other studies.
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CFU Quantification
Typical results for the cell-dilution CFU quantification method are shown in a M.
JLS example in Figure 4.6. The CFU concentration in this figure would be 1.1 x 108
CFU/ml according to the most dilute spot and would be 6.1 x 107 CFU/ml according to
the next most dilute spot, yielding an average of 8.55 x 107 CFU/ml and a standard
deviation of 3 x 107. Spectrophotometric CFU quantification was attempted in
preliminary studies. However, mycobacterial clumping decreased accuracy, and the
results of such attempts are not shown here. While the cell dilution CFU quantification
method was more laborious, it proved to be more precise.
EtOH/MeOH Toxicity Testing
The cell growth/death results for M. KMS in MeOH and EtOH over a six-day
period are shown in Figures 4.7 and 4.8, respectively. Of both solvents, only the 4%
EtOH concentration caused a decrease in M. KMS CFU population (10-fold decrease in
the first four days), which rebounded somewhat in the following two days. There were
no significant differences seen between any of the other solvent concentrations and their
no-solvent controls. It was necessary to evaluate the toxicity of EtOH and MeOH to
ensure any inhibitory/bactericidal effect was not due to the solvents. MeOH and EtOH
were the solvents chosen for this study since they were the most commonly used SJW
solvents in literature. The lower toxicity of MeOH reinforced the decision to use it as the
SJW solvent for the duration of these studies. In the MBC studies, the 2% (v/v)
concentration was found to be the minimum organic solvent concentration that would still
allow a high enough SJW crude extract concentration to consistently inhibit all
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mycobacteria at more than one assayed concentration. Hence, SJW extracts of various
concentrations were most commonly added to cultures at 2% (v/v) concentration for the
inhibitory/bactericidal studies.
Crude Extract MIC Studies
Agar plates from the inhibitory studies are shown in Figure 4.9. A trend of no
growth at the higher SJW concentrations and growth at the lower SJW concentrations
was seen, but a distinct threshold was not seen. No growth was seen from the 8% - 1%
plates (except one of the 1% plates), small growth was seen on the 0.5% - 0.25% plates
and growth was seen on all other plates (except one of the 0.03% plates). Therefore, a
tentative MIC value from these plates would be between the 0.5% and 1% concentrations
(of 1X stock solution). However, with the understanding of the inhibitory effects of
EtOH, which was shown to adversely affect cell growth at a 4% concentration in the
solvent toxicity studies, inhibitory effect cannot be exclusively credited to the SJW
extract. Since any EtOH inhibition was uniform throughout all the plates (all plates had
the same volume added, regardless of SJW concentration of the additive) and would only
serve to reduce CFU population, the 0.5% - 1.0% 1X MIC value should be fairly
accurate.
Crude Extract MBC Studies
A typical set of CFU dilution growth plates for each strain, along with zoomed-in
views of colonies from these strains, are shown in Figure 4.10. All plates shown are from
the 48-hr time point except B. subtilis, which is from the 24-hr time point (shown for
clarity). The absence of growth of cells that had been exposed to higher SJW
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concentrations can be seen. The MeOH control and no-MeOH/SJW control can be seen
at the bottom two sections of the bottom plate in each image.
Typical growth/death results are shown in Figures 4.11 through 4.17. MBC
values are shown in Table 4.3. Since the definition of MBC is the minimum
concentration that kills ≥ 99.9% (three orders of magnitude) of the culture over a given
period of time (which is considered 72 hr for this study), the 0.67 mg extract/ml culture
would be considered a bactericidal concentration for M. MCS and M. phlei. From most
sensitive to least sensitive, the results show concentration sensitivity to the SJW MeOH
extract in the following order: M. JLS and M. KMS, M. phlei, M. MCS, B. subtilis, M.
smegmatis, and E. coli, which showed no sensitivity. It should be noted that earlier
studies showed that even though these differences exist in sensitivity over time, it was
found that B. subtilis reacted the most quickly. This conclusion was derived from earlier
MBC studies, which considered the “time 0” time point to be immediately after adding
the SJW extract. Within the 0.5-hr to 1-hr timeframe it took to perform the first CFU
quantification after SJW extract addition, the B. subtilis cultures had already been killed
at the higher concentrations. This effect is seen in Figure 4.18. The 2.66 mg extract/ml
concentration killed the cells within this timeframe, and the 0.67 and 1.33 mg extract/ml
concentrations saw a rebound in cell growth over two days. The rebound effect may be
attributable to the fact that this cell dilution method does not detect CFU concentrations
under 100 cells/ml and to the relatively fast doubling time of 30-45 min (depending on
medium) for B. subtilis (Leitch and Collier, 1996). This growth may also be attributable
to resistant mutants and merits further study. This immediate effect was not seen in any
other strain assayed.
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It should be noted that Tween 80 (0.05% final concentration) was used in these
crude extract MBC studies. In the light of the purified compound MBC results shown
below, the MBC values would likely be lower in the absence of Tween 80.
Purified Compound MBC Studies
Hfn Inhibition and the Effect of Tween 80. In the absence of Tween 80, Hfn
caused bactericidal effects at the 26 µg/ml and 52 µg/ml concentrations (within 48 hr)
and had inhibitory effects at the 6 µg/ml and 13 µg/ml concentrations (Figure 4.19). In
the presence of Tween 80 at 0.05% v/v concentration, no effect from Hfn, bactericidal or
inhibitory, was seen (Figure 4.20).
The MBC values shown here are at least 65 times higher than the Hfn
concentrations (approximately 0.4 µg/ml) found in rat and human blood after a high dose
(1200 mg) of SJW extract taken orally (Biber et al., 1998). Therefore, oral
administration of the SJW herb does not reach adequate Hfn concentrations for
mycobacterial death. Studies involving Hfn administration techniques that bypass the
digestive system for direct treatment, such as the use of inhalants (Gelperina et al., 2005;
Shoyele and Cawthorne, 2006; Chow et al., 2007; Sung et al., 2007; Jaafar-Maalej et al.,
2009; Salama et al., 2009), merit investigation.
When keeping the Hfn concentration constant at 46 µg/ml (concentration in 1:50
dilution (2% v/v) of 1X crude extract) and varying the Tween 80 concentration from
0.003-0.1%, a decreasing ability of Hfn to inhibit mycobacterial growth was seen with
increasing Tween 80 concentration (Figure 4.21). The 0.1% Tween 80 concentration had
the same approximate CFU count as the no-Tween80/Hfn control. A Tween 80 dose-
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dependent CFU count reduction was observed with the 0.025% and 0.05%
concentrations, and the more dilute Tween 80 concentrations reached CFU counts of 100
CFU/ml or less over the 72-hr study.
Effect of Tween 80 on MeOH Crude Extract. The crude extract controls showed a
similar pattern as Hfn. In the absence of Tween 80, cell death was seen in all
concentrations assayed: 0.33 (1/8X), 0.67 (1/4X), 1.33 (1/2X), and 2.66 (1X), mg
extract/ml, which contained 6, 11, 23, and 46 µg/ml Hfn, respectively (Figure 4.22). In
the presence of Tween 80 (0.05%), the crude extract caused bactericidal effects in the
1.33 mg extract/ml (23 µg/ml Hfn) only (2.7 mg extract/ml not tested) (Figure 4.23).
Slight inhibitory effects (10-fold less) were seen in the 0.67 mg extract/ml (11 µg/ml
Hfn).
The difference in inhibitory effect seen in the absence and presence of Tween 80
is significant. This finding is important for any antimicrobial study for mycobacteria
involving Tween 80; it may invite a reinvestigation of reported MIC/MBC values of
other antimycobacterial agents if Tween 80 was used in the studies. Whether the cause of
this effect is an interaction between Tween 80 and Hfn or between Tween 80 and the
bacterial cell wall remains to be studied. It is known that Tween 80 affects the outermost
layer of the cell wall (Parish and Stoker, 1998), which understanding could help in
determining the mechanism of action for Hfn. Another possible explanation for this
effect is the formation of Tween 80 micelles around Hfn molecules, preventing the
otherwise inhibitory Hfn from working. Also, the fact that inhibition was seen in the
crude extract samples containing 23 µg Hfn/ml, but not in the pure Hfn (23 µg/ml)
samples when in the presence of Tween 80, suggests that the crude extract contains
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compounds which either stabilize Hfn, interact with Tween 80, or interact with the
bacterial cell wall to allow inhibition to occur at a higher degree than pure Hfn.
Effect of Hypericin and Pseudohypericin. No bactericidal or inhibitory effects
were seen in the Hpn or Phn samples at any assayed concentrations (Figures 4.24 and
4.25). However, a synergistic effect of these compounds with each other or with Hfn was
not studied and merits investigation.
Effect of Light on Inhibition. No significant effect of light on Hfn inhibition of
M. KMS was seen. Though the Hfn concentrations were not high enough to achieve
MBC values, dose responses were seen in both the light-exposed tubes (Figure 4.26) and
the tubes kept in the dark (Figure 4.27); these responses were remarkably similar. Due to
an experimental error in the 24-hr CFU count for the control of the light samples, the
value for the control from the dark samples was used for this particular time point. From
the results of these studies, it was decided to not investigate the effects of light any
further.
SEM Imaging
The results from SEM imaging are shown in Figures 4.28 – 4.32. Figure 4.28
shows untreated images of all the bacteria used in the MBC experiments. Figure 4.29
shows the untreated image of M. KMS again along with its response to the 1.33 mg
extract/ml crude extract treatment at times 4, 8, and 24 hr. Figure 4.30 shows the
progressive response of M. smegmatis to 2.66 mg extract/ml crude extract treatment at
times 12, 24, and 48 hr in addition to its control. Figure 4.31 shows the B. subtilis
response to 1.33 mg extract/ml treatment at times 30 min, 1 hr, and 2 hr in addition to its
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control. Figure 4.32 shows the response of E. coli to 2.66 mg extract/ml treatment after
72 hr in addition to its control.
While no visible or experimental effect can be seen in the response of E. coli to
SJW (other than a darkening of the media beyond the darkness of the extract addition,
which effect was not studied), there appears to be a trend in the response of the SJWsusceptible organisms to the crude extract: (1) an increase in field debris - whether or not
this is cell debris or extract debris (<0.2 µm because of filtered extract) is uncertain, but it
is suspected to be cell debris, as it is not seen in the treated E. coli images; (2) a
“beading,” or blistering effect in the cell wall; and (3) cell wall splitting, cracking, or
rupturing, which leads to spilling of the cell contents. Cell death is known to occur
before the third part of the cell degradation trend, based on times from the MBC results.
It is suspected that cell death occurs closer to the second phase. These results support the
MBC results, which show B. subtilis as having the most rapid SJW response. These
results also suggest that there is either a direct chemical interaction with the cell wall or
an interference with genetic cell wall maintenance.
Conclusions
The results from this chapter show a M. tuberculosis homology comparison to all
nonpathogenic, genetically sequenced mycobacteria for M. MCS (72%), M. smegmatis
(69%), M. KMS (69%), M. vanbaalenii (67%), M. JLS (66%), and M. gilvum (65%).
SJW compounds are effective at inhibiting every currently sequenced, nonpathogenic
Mycobacterium isolate, as well as M. phlei, which has not yet been sequenced. There is
no visible difference in the level of growth of mycobacteria between LB media and MB
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media, but LB media produces more vibrant mycobacterial pigmentation, which makes
colonies easier to see and quantify. The five Mycobacterium isolates assayed in the MBC
studies are resistant to ampicillin, but cell pigmentation is reduced when grown on Amp
agar media. EtOH has a higher toxicity to M. KMS than MeOH, though only in reducing
CFU population 10-fold at the highest concentration tested (4% v/v). MeOH has no
toxicity to any of the assayed strains at the concentrations most often used in this study
(2-4% v/v). No inhibition difference has been seen between SJW extracts of different
solvents, though this has only been assayed at a 4% (v/v) concentration of an extract from
a 0.36 mg herb/ml solvent solution. Depending on concentration, the MeOH SJW extract
is inhibitory and bactericidal to (mg extract/ml culture) M. JLS (0.33-0.67), M. KMS
(0.33-0.67), M. MCS (0.33-0.67), M. smegmatis (1.33-2.66), M. phlei (0.33-0.67), and the
Gram-positive control B. subtilis (0.67-1.33); it has no effect on the viability of E. coli at
the concentrations assayed.
An MIC value for the SJW EtOH extract has been determined for M. KMS (0.51% v/v of an extract from a 0.36 mg herb/ml solvent solution) using the dilution-in-agar
method. In the absence of Tween 80, Hfn has a MBC of 6-13 µg/ml for M. JLS. Tween
80 represses Hfn inhibition of M. JLS at Tween 80 concentrations of ≥ 0.025% (v/v) at 46
µg/ml Hfn (Hfn concentration in 2.66 mg extract/ml); this may be due to micelle
formation around Hfn molecules or an interaction of Tween 80 with the cell wall. Tween
80 also raises the MBC of M. JLS when used with the crude extract, but not to the degree
seen with pure Hfn, even if both solutions have the same Hfn concentration; this may be
due to a synergistic inhibitory effect of another SJW compound with Hfn, protection of
Hfn from the effects of Tween 80, or a direct interaction of crude extract compounds with
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the cell wall. Tween 80, however, helps to reduce clumping and solubilize the SJW
extract in culture and makes the cell dilution CFU quantification method more accurate.
Hpn and Phn do not have an inhibitory effect on M. JLS at the concentrations assayed.
Light does not appear to affect the inhibitory effect of Hfn. SEM imaging suggests that
SJW has an effect on the cell wall integrity/maintenance of the susceptible organisms,
which knowledge should help in future studies of determining the mechanism of action.
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Table 4.1 Inhibition demonstration of SJW extracts of various solvents and various
SJW brands after one week of growth on crude-extract-containing plates (4% extract,
v/v). Degree of growth is indicated by number of plus signs, and no growth is indicated
by a minus sign. Some responses were not determined (ND) due to fungal
contamination. Controls (shown at bottom) contained solvent only.
Nature’s	
  Way	
  
M.	
  JLS	
  
M.	
  KMS	
  
M.	
  MCS	
  
M.	
  van.	
  PYR-‐1	
  
M.	
  gilvum	
  PYR-‐GCK	
  
P.	
  putida	
  
	
  

NOW	
  
M.	
  JLS	
  
M.	
  KMS	
  
M.	
  MCS	
  
M.	
  van.	
  PYR-‐1	
  
M.	
  gilvum	
  PYR-‐GCK	
  
P.	
  putida	
  
	
  
GNC	
  
M.	
  JLS	
  
M.	
  KMS	
  
M.	
  MCS	
  
M.	
  van.	
  PYR-‐1	
  
M.	
  gilvum	
  PYR-‐GCK	
  
P.	
  putida	
  
	
  
Controls	
  (solvent	
  only)	
  
M.	
  JLS	
  
M.	
  KMS	
  
M.	
  MCS	
  
M.	
  van.	
  PYR-‐1	
  
M.	
  gilvum	
  PYR-‐GCK	
  
P.	
  putida	
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-‐	
  
ND	
  
-‐	
  
-‐	
  
-‐	
  
+++	
  
	
  
	
  
-‐	
  
ND	
  
-‐	
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-‐	
  
+++	
  
	
  
	
  
-‐	
  
-‐	
  
-‐	
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+++	
  
	
  
	
  
+++	
  
ND	
  
+++	
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+++	
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+++	
  
+++	
  
+++	
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-‐	
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-‐	
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++	
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-‐	
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+++	
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+++	
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Table 4.2 Inhibition demonstration of SJW extracts of various solvents and various
SJW brands after two weeks of growth on crude-extract-containing plates (4% extract,
v/v). Degree of growth is indicated by number of plus signs, and no growth is indicated
by a minus sign. Some responses were not determined (ND) due to fungal
contamination. Controls (shown at bottom) contained solvent only.
Nature’s	
  Way	
  
M.	
  JLS	
  
M.	
  KMS	
  
M.	
  MCS	
  
M.	
  van.	
  PYR-‐1	
  
M.	
  gilvum	
  PYR-‐GCK	
  
P.	
  putida	
  
	
  
NOW	
  
M.	
  JLS	
  
M.	
  KMS	
  
M.	
  MCS	
  
M.	
  van.	
  PYR-‐1	
  
M.	
  gilvum	
  PYR-‐GCK	
  
P.	
  putida	
  
	
  
GNC	
  
M.	
  JLS	
  
M.	
  KMS	
  
M.	
  MCS	
  
M.	
  van.	
  PYR-‐1	
  
M.	
  gilvum	
  PYR-‐GCK	
  
P.	
  putida	
  
	
  
Controls	
  (solvent	
  only)	
  
M.	
  JLS	
  
M.	
  KMS	
  
M.	
  MCS	
  
M.	
  van.	
  PYR-‐1	
  
M.	
  gilvum	
  PYR-‐GCK	
  
P.	
  putida	
  

Acetone	
  
-‐	
  
ND	
  
-‐	
  
-‐	
  
+	
  
+++	
  
	
  
	
  
ND	
  
ND	
  
-‐	
  
-‐	
  
-‐	
  
+++	
  
	
  
	
  
-‐	
  
-‐	
  
-‐	
  
-‐	
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+++	
  
	
  
	
  
+++	
  
ND	
  
++	
  
++	
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+++	
  

Ethanol	
  
-‐	
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ND	
  
+++	
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-‐	
  
-‐	
  
-‐	
  
-‐	
  
+++	
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-‐	
  
+++	
  
	
  
	
  
+++	
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-‐	
  
+++	
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Table 4.3 Minimum bactericidal concentrations for the
seven MBC-assayed strains.
Strain	
  
M.	
  JLS	
  
M.	
  KMS	
  
M.	
  MCS	
  
M.	
  smegmatis	
  
M.	
  phlei	
  
E.	
  coli	
  
B.	
  subtilis	
  

SJW	
  MBC	
  (mg	
  extract/ml	
  culture)	
  
0.33-‐0.67	
  
0.33-‐0.67	
  
0.33-‐0.67	
  
1.33-‐2.66	
  
0.33-‐0.67	
  
N/A	
  
0.67-‐1.33	
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Figure 4.1 Venn diagram for genetic similarity of all currently sequenced,
nonpathogenic mycobacteria to M. tuberculosis. Comparisons are made using amino
acid sequences. Non-percentage numbers indicate number of genes. Outer percentages
indicate genome unique to each Mycobacterium isolate. Middle percentages indicate
percentage of each isolate genome similar to M. tuberculosis. Inner percentages indicate
percentage of M. tuberculosis genome incorporated in each isolate (of greatest interest for
this study).

Figure 4.2 The five Mycobacterium strains used in the MBC studies: (starting in top
right, going counterclockwise) M. JLS, M. KMS, M. MCS, M. smegmatis, and M. phlei.
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Figure 4.3 Growth plates for demonstration of inhibitory effect and comparison of
extracts of different solvents and different SJW brands. Only the plates for the GNC
brand are shown here. Organisms on plate are as follows (starting at top, going
counterclockwise): P. putida (G- control), M. vanbaalenii, M. gilvum, M. MCS, M. JLS,
M. KMS. Because this particular extract used was not filtered, fungal growth occurred in
several of the M. KMS sections; these were classified as “not determined.”
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Middlebrook	
  Media	
  

M.	
  phlei	
  

M.	
  smegmatis	
  

M.	
  MCS	
  

M.	
  KMS	
  

M.	
  JLS	
  

LB	
  Media	
  

Figure 4.4 Comparison of mycobacterial growth on LB
and MB media. Dark background behind plates is to
show contrast. For the USU isolates (top three), growth
on LB media provided higher bacterial visibility.

66	
  
	
  

Figure 4.5 Growth comparison of five Mycobacterium isolates on
antibiotic-free LB (left) plates and ampicillin-containing LB (50 µg/ml,
right) plates. Organisms assayed were (starting at top and going
clockwise) M. JLS, M. KMS, M. MCS, M. smegmatis, and M. phlei. A
higher degree of cell pigmentation was seen on the antibiotic-free plates,
so antibiotic-free media was used in all studies for consistency and to
enable the easier use of the cell dilution method for CFU quantification.

Figure 4.6. Typical example of CFU
quantification results using the cell dilution
method (M. JLS). The CFU count for this
sample would be 1.1 x 108 CFU/ml according
to the most dilute spot and would be 6.1 x 107
CFU/ml according to the next lest dilute spot,
yielding an average of 8.55 x 107 CFU/ml
with a standard deviation of 3 x 107.
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Figure 4.7 Effect of MeOH on M. KMS viability. Concentrations assayed (v/v) were at
final working volumes of 0.5%, 1.0%, 2.0%, and 4.0%, with a no-MeOH control
included. Error bars are standard deviation (SD).

Figure 4.8 Effect of EtOH on M. KMS viability. Concentrations assayed (v/v) were at
final working volumes of 0.5%, 1.0%, 2.0%, and 4.0%, with a no-EtOH control included.
Error bars are SD.
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Figure 4.9 Growth plates from dilution-in-agar MIC study of SJW EtOH extract.
Starting from upper left two plates and reading in columns, concentrations (% of 1X
stock solution) were 8%, 4%, 3%, 2%, 1%, 0.5%, 0.25%, 0.13%, 0.07%, 0.03%, and 0%,
performed in duplicate plates. Organism key is on bottom right.
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Figure 4.10 Typical cell dilution plates used for CFU quantification in
MBC studies. Concentrations assayed were 2X, 1X, 1/2X, 1/4X, 1/8X,
and 1/16X, representing 4.5, 2.7, 1.3, 0.7, and 0.3 mg extract/ml,
respectively. The bottom right figures show zoomed in views of
colonies from the dilutions to show cell morphology. MeOH-only
controls (denoted “MeOH”) and no-MeOH/SJW (denoted “None”) are
the bottom two sections of the bottom plate of each isolate image.
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Figure 4.11 Typical growth/death results of M. JLS from the crude extract MBC studies.
SJW MeOH extracts of various concentrations were used at 2% (v/v) the total volume:
0.17, 0.33, 0.67, 1.33, and 2.66 mg extract/ml culture. The MBC was between 0.33-0.67
mg extract/ml. Error bars are SD.

Figure 4.12 Typical growth/death results of M. KMS from the crude extract MBC
studies. SJW MeOH extracts of various concentrations were used at 2% (v/v) the total
volume: 0.17, 0.33, 0.67, 1.33, and 2.66 mg extract/ml culture. The MBC was between
0.33-0.67 mg extract/ml. Error bars are SD.
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Figure 4.13 Typical growth/death results of M. MCS from the crude extract MBC
studies. SJW MeOH extracts of various concentrations were used at 2% (v/v) the total
volume: 0.17, 0.33, 0.67, 1.33, and 2.66 mg extract/ml culture. The MBC was between
0.33-0.67 mg extract/ml. Error bars are SD.

Figure 4.14 Typical growth/death results of M. smegmatis from the crude extract MBC
studies. SJW MeOH extracts of various concentrations were used at 2% (v/v) the total
volume: 0.33, 0.67, 1.33, 2.66, and 4.46 mg extract/ml culture. The MBC was between
1.33-2.66 mg extract/ml. Error bars are SD.
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Figure 4.15 Typical growth/death results of M. phlei from the crude extract MBC
studies. SJW MeOH extracts of various concentrations were used at 2% (v/v) the total
volume: 0.17, 0.33, 0.67, 1.33, and 2.66 mg extract/ml culture. The MBC was between
0.33-0.67 mg extract/ml. Error bars are SD.

Figure 4.16 Typical growth/death results of E. coli from the crude extract MBC studies.
SJW MeOH extracts of various concentrations were used at 2% (v/v) the total volume:
0.33, 0.67, 1.33, 2.66, and 4.46 mg extract/ml culture. There was no SJW MBC for this
strain. Error bars are SD.
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Figure 4.17 Typical growth/death results of B. subtilis from the crude extract MBC
studies. SJW MeOH extracts of various concentrations were used at 2% (v/v) the total
volume: 0.17, 0.33, 0.67, 1.33, and 2.66 mg extract/ml culture. The MBC was between
0.67-1.33 mg extract/ml. Error bars are SD.
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Figure 4.18 The time course of SJW effect on B. subtilis. In early MBC studies, the
“time 0” CFU count was taken immediately after adding the SJW extract, which would
have been within about 1 hr. Cell growth rebound was seen in the 0.67 mg/ml and 1.33
mg/ml concentrations. The Mycobacterium isolates did not see such a rapid inhibition
response. Error bars are SD.
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Figure 4.19 Growth/inhibition results for M. JLS treated with Hfn in the absence of
Tween 80. Concentrations assayed were 6, 13, 26, and 52 µg/ml culture. The MBC was
6-13 µg/ml. Error bars are SD.
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Figure 4.20 Growth/inhibition results for M. JLS treated with Hfn in the presence of
Tween 80 (0.05% v/v). Concentrations assayed were 3, 6, 11, and 23 µg/ml culture.
There was no MBC for these samples. Error bars are SD.
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Figure 4.21 Tween 80 repression of Hfn inhibition of M. JLS with all samples except the
control containing 46 µg/ml Hfn. Decreasing inhibition occurred with increasing Tween
80 concentration. The 0.1% concentration had similar CFU counts as the No-Tween
80/Hfn control. Decreasing CFU counts were seen in the 0.05% and 0.025%
concentrations, and all lower Tween 80 concentrations reached CFU counts of 100
CFU/ml or less over the 72-hr study. Error bars are SD.
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Figure 4.22 Growth/inhibition results for M. JLS treated with crude extract (for
comparison in the pure compounds MBC studies) in the absence of Tween 80.
Concentrations assayed were 0.33, 0.67, 1.33, and 2.66 mg extract/ml culture. Inhibition
was seen in all crude extract concentrations in this study. Error bars are SD.
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Figure 4.23 Growth/inhibition results for M. JLS treated with crude extract (for
comparison in the pure compounds MBC studies) in the presence of Tween 80 (0.05%
v/v). Concentrations assayed were 0.17, 0.33, 0.67, and 1.33 mg extract/ml culture. The
MBC was between 0.67-1.33 mg extract/ml. Error bars are SD.
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Figure 4.24 Growth/inhibition results for M. JLS at various concentrations of Hpn
without Tween 80 added to the culture. Concentrations assayed were 3, 7, 13, and 27 µg
Hpn/ml culture. No concentrations reached MBC levels. Error bars are SD.
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Figure 4.25 Growth/inhibition results for M. JLS at various concentrations of Phn
without Tween 80 added to the culture. Concentrations assayed were 3, 6, 13, and 25 µg
Phn/ml culture. No concentrations reached MBC levels. Error bars are SD.
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Figure 4.26 Growth/inhibition results for the light-exposed samples (M. KMS) of the
light/dark Hfn study. Concentrations assayed were 0.1, 1, and 5 µg Hfn/ml culture. The
samples in light and dark had nearly identical results. Error bars are SD.
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Figure 4.27 Growth/inhibition curves for the foil-wrapped samples (M. KMS) of the
light/dark Hfn study. Concentrations assayed were 0.1, 1, and 5 µg Hfn/ml culture. The
samples in light and dark had nearly identical results. Error bars are SD.
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Figure 4.28 SEM images of untreated strains used in the SJW inhibitory/bactericidal
assays. (a) M. JLS, (b) M. KMS, (c) M. MCS, (d) M. smegmatis, (e) M. phlei, (f) E.
coli, (g) B. subtilis
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Figure 4.29 SEM images of the progression of M. KMS response to
SJW MeOH crude extract (1.33 mg extract/ml). Exposure at times (a) 0,
(b) 4 hr, (c) 8 hr, and (d) 24 hr.
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Figure 4.30 SEM images of the progression of M. smegmatis response
to SJW MeOH crude extract (2.66 mg extract/ml). Exposure at times (a)
0, (b) 12 hr, (c) 24 hr, and (d) 48 hr.
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Figure 4.31 SEM images of the progression of B. subtilis response to
SJW MeOH crude extract (1.33 mg extract/ml). Exposure at times (a) 0,
(b) 4 hr, (c) 8 hr, and (d) 24 hr.
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Figure 4.32 SEM images of the response of E. coli to SJW MeOH
crude extract (2.66 mg extract/ml). Exposure at times (a) 0 and (b) 72
hr.
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CHAPTER 5
EFFECT OF HYPERICUM PERFORATUM ON HUMAN
ALVEOLAR EPITHELIAL CELLS
Introduction
The aim of this study was to investigate the potential of using one or more of the
SJW compounds as an inhalant for TB. Therefore it was decided to investigate the effect
of these compounds on the human carcinomic alveolar epithelial lung cell line A549.
Studies were performed that investigated the effects of MeOH, SJW MeOH crude extract,
Hpn, Phn, Hfn, and M. JLS cells on A549 cell viability.
Materials and Methods
A549 Media (Ham’s) Preparation
The protocol for A549 media (Ham’s) preparation is in the Appendix.
A549 Cell Culturing
A549 Culturing from Freezer Stock. Freezer stocks of A549 (1-ml stocks), about
16th subculture, were obtained from Dr. Soonjo Kwon from the USU Biological
Engineering Tissue Engineering Laboratory. Cell cultures were started from -80ºC
freezer stocks by adding the cells to a tissue-culture-treated T25 (25 cm2) or T75 flask
(75 cm2) (BD, Fisher Scientific, Pittsburgh, PA). Warmed (37ºC) media was then added
to the cells (5 ml for T25 or 12 ml for T75). If the flask did not have a vent cap, the lid
was left slightly open to allow gas exchange. Cells were incubated in a CO2 incubator
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(model 3531, Fisher Scientific, Pittsburgh, PA) at 37ºC and 5% CO2. Media was
changed every 2 or 3 days.
Subculturing. To subculture the cells, the old media was removed, and 0.05%
trypsin EDTA (Invitrogen, Carlsbad, CA) was added in volumes of 50-250 µl/cm2. The
flasks were then incubated at 37ºC for 5-15 min until the cells had completely detached
from the surface. Visual confirmation of cell detachment was done using an inverted
microscope. About 5 ml media was added to inhibit the trypsin, and this cell solution
was transferred to a 15-ml centrifuge tube. Another 5-ml media was added to rinse any
remaining cells from the flask and was also added to the centrifuge tube. The tube was
centrifuged for 10 min at 1000 RPM (834 RCF), and supernatant was discarded. A 4-ml
volume of warmed media was added, and the cells were gently resuspended. A simple
subculture consisted of splitting this volume evenly between two or more flasks and
bringing the culture volume to the correct level with media.
Cell Seeding at Specific Densities in Well Plates. If a specific cell seeding density
was desired, a Hausser Scientific Bright-Line hemacytometer (Fisher, Pittsburgh, PA)
was used to determine cell concentration (Figure 5.1). After cleaning the cell chamber
surface and cover slide, the cover slide was placed firmly over the two chambers, and 10
µl of resuspended cell solution was added to one of the chambers via an injection slot.
Capillary action filled the chamber. Using an inverted microscope, four cell counts were
taken from four 1 mm2 x 0.1 mm deep squares (divided into 16 smaller squares for easier
counting). The counts were averaged and multiplied by 104 to obtain cells/ml. Cell
concentrations were adjusted by diluting with media and adding to a 6-well (9.6
cm2/well) or 48-well (0.75 cm2/well) tissue culture plate (BD Falcon, Fisher, Pittsburgh,
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PA). Seeding densities ranged from 6.6x104 to 2.6x105 cells/cm2 in the A549 viability
studies (approximately 1.3x104 cells/ml would reach confluency in 48 hr).
Freezer Stock Preparation. Freezer stocks of the A549 cells were made by
preparing a 5% (v/v) dimethyl sulfoxide (DMSO) (Fisher Bioreagents, Pittsburgh, PA)
cell solution after the centrifugation and resuspension steps of subculturing. The solution
was aliquoted into 1.5-ml Bio Plas microcentrifuge tubes (Fisher, Pittsburgh, PA) and
stored at -70ºC. Cells were stored in cryopreservation tubes in liquid nitrogen (-196ºC)
for long-term storage.
Treatments of A549 Cell Cultures
Various treatments were assayed for effect on A549 cell viability: MeOH, SJW
MeOH crude extract, Hpn, Phn, Hfn, and M. JLS cells. Treatments were always added to
confluent cultures after the first (“time 0”) sample was taken. The MeOH treatment was
assayed in 6-well plates, and all other treatments were assayed in 48-well plates. MeOH
was added at four concentrations in triplicate two weeks after seeding (2.6x104
cells/cm2). SJW MeOH crude extract (in triplicate) and Hfn (in duplicate) were added at
various concentrations (always ≤ 2% v/v) three days after seeding (2.6x105 cells/cm2) for
one study and one week after seeding (6.6x104 cells/cm2) for another study using glass
syringes (Hamilton, Reno, NV). Hpn and Phn were added in triplicate at various
concentrations three days after seeding (2.6x105 cells/cm2) using glass syringes. M. JLS
cells were added in duplicate at 5x106 cells/cm2 to A549 cultures one week after seeding
(6.6x104 cells/cm2); cell concentration was determined using an average of four 0.04 mm2
squares (Figure 5.1) of the hemacytometer.
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A549 Viability Testing
Pierce Bicinchoninic Acid (BCA) Total Protein Assay. To harvest cell material
for the Pierce BCA total protein assay, media was removed from the plate wells, and each
well was rinsed with phosphate-buffered saline (PBS) (HyClone, Fisher, Pittsburgh, PA).
A 1% (v/v)(aq) Triton X-100 (Fisher, Pittsburgh, PA) solution was added to the cells in
consistent volumes, at least enough to cover the cells (650 µl/cm2 was typical), for cell
lysis. The cells were then incubated at 37ºC for 45 min, then thoroughly scraped off
using a 1-ml pipette tip and resuspended in the Triton solution. The cells were
transferred to 1.5-ml microcentrifuge tubes and stored at -80ºC until a Pierce BCA total
protein assay (Thermo Scientific, Rockford, IL) was performed. The protocol used was
supplied with the kit (Thermo, 2010).
Direct Cell Counting. To harvest cells for direct cell counting, cells were rinsed
with PBS, detached with 200 µl of 0.05% trypsin EDTA (in like manner as was done
when subculturing), and added to 300 µl Ham’s media for trypsin inactivation. Direct
cell counts were then taken using the hemacytometer (Figure 5.1). Brightfield images
were taken for many of the samples before cell removal (in wells) and after cell counting
(while on the hemacytometer) using a Nikon Fluorescence Microscope (Eclipse Ti-DH,
Nikon, Melville, NY) with attached camera (Cool Snap HQ2, Photometrics, Tucson, AZ).
Statistical Analysis. The direct cell counting results of the various A549
treatments were analyzed for statistically significant differences between each other using
the General Linear Modeling (GLM) Procedure with SAS statistical analysis software.
The results were analyzed as a 4x10x2 factorial design, with 4 levels of time, 10 levels of
“additives” (including the controls), and 2 replicates (each replicate value was taken by
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averaging the four hemacytometer counts of each cell sample). Results were then
grouped by statistically significant differences using the Ryan-Einot-Gabriel-Welsh q
(REGWQ) test.
Testing Mycobacterial Growth in Ham’s
Media
The five Mycobacterium strains assayed in the MBC studies were tested for
ability to grow in Ham’s media by preparing two sets of 12-ml culture tubes, each tube
containing 5-ml Ham’s media. One set contained no antibiotics, and the other set
contained penicillin-streptomycin (100 U/ml and 100 µg/ml, respectively). Each tube was
inoculated with 100 µl freezer stock of bacteria and incubated at the proper temperatures.
Growth was observed after eight days.
Results and Discussion
Effects of Treatments on A549 Cell
Viability
Statistical Analysis. The residuals vs. normal percentiles plot of the A549 cell
counts from the direct cell counting study showed adequate homoscedasticity. Partial R2
values of the treatments (proportion contribution to the final outcome, which all add to 1),
as well as their degrees of freedom (DF) (number of values that are free to vary in the
final statistical calculation), F-values (used to calculate p-values) and p-values (used to
show statistical significance if under 0.05), are shown in Table 5.1. SJW additive had the
greatest effect (partial R2 0.441), followed by the interaction between additive and time
(partial R2 0.282), followed by time (partial R2 0.240). REGWQ grouping for the
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additives is shown in Table 5.2, with means of different letters being significantly
different from each other. The groupings are as follows: (A) the MeOH control, noMeOH control, M. JLS, and Hfn 3 µg/ml samples; (B) the Hfn 6 µg/ml, Hfn 11 µg/ml,
and Hfn 23 µg/ml samples; (C) the Hfn 11 µg/ml, Hfn 23 µg/ml, and Hfn 46 µg/ml
samples; (D) the Hfn 46 µg/ml, crude 1.33 mg extract/ml, and crude 2.66 mg extract/ml
samples.
MeOH Treatment. Results for the effect of MeOH on A549 viability are shown in
Figure 5.2. The higher protein concentrations from these plates (due to suspending the
cells in a smaller relative volume of Triton X-100 than the assays that used 48-well
plates) were corrected by dividing by the fold-size difference in the 6-well and 48-well
surface area (9.6/0.75 = 12.8). The order of total protein concentration (high to low) was
0%, 1%, 3%, and 2%, with a mean of 48.5 µg/ml +/- 2.2 (std. dev.). There was no
pattern seen in the treatment responses. No statistically significant differences were seen
between the concentrations using the GLM procedure in the SAS (3 DF, F-value: 4.00, pvalue: 0.0518) program. Therefore, MeOH concentrations up through 3% did not have
an effect on A549 viability.
SJW MeOH Crude Extract Treatment. The Pierce BCA protein assay was not
effective at quantifying protein from the crude extract treatment due to the brown cell
staining that the cells received from the crude extract. This caused OD readings that were
much higher than the controls (Figure 5.3). Therefore, efforts to quantify A549 cells
treated with crude extract with colorimetric assays were abandoned, and the direct cell
counting method was used.
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Results showing the use of the direct cell count method are shown in Figure 5.4.
Cell death in both of the crude extract samples (1.33 and 2.66 mg extract/ml) was seen
after one day. Cell death was interpreted to be the absence of cells after PBS rinsing or a
non-round, shredded, cell morphology (different from all other viable cells, which were
round and intact). Such morphology is seen in the crude-extract-exposed A549 cell
images in Figures 5.5-5.7. Viable cells (as seen in the controls) were flat, adhered to the
plate, and tessellated; nonviable cells were round and detached (at least to some degree).
It should be noted that the cells treated with crude extract did not detach from the well
surface or disaggregate with trypsin treatment, even after rinsing off the media with PBS.
Mild scraping was required to remove the cells from the wells. This same effect was
seen with the A549 samples in the protein assay after crude extract treatment; they also
did not detach with PBS rinsing. It is unknown why this occurred, but it is possible that
the crude extract contains a trypsin inhibitor. It is also possible that the crude extract
contains one or more compounds that change the properties of the A549 cell membranes,
causing them to adhere to the well surface and each other, even after cell death.
Hyperforin Treatment. The Hfn-treated cells were the only cells with a
conclusive effect from the Pierce BCA protein assay (Figure 5.3). After 2 days of
exposure, rinsing with PBS completely removed the cells. The direct cell count study
revealed a dose-dependent response of the cells to Hfn, with the 11, 23, and 46 µg/ml
concentrations causing complete cell death. The half maximal lethal dose (LD50)
(concentration that kills half the cell population) for the A549 cells in response to Hfn
was 3-6 µg/ml (5.6-11.2 µmol/L). There was usually no cell debris left behind after
rinsing dead cells with PBS; however, cell debris was found in some Hfn samples and
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were included in the images (see Figures 5.5-5.7). Contrast between live and dead cells
is easily apparent in the 3 and 6 µg Hfn/ml images in Figure 5.7.
Thus far, no study has been found to investigate the effect of Hfn on the A549 cell
line. Though the results from this study do not show a lack of Hfn toxicity to primary
human lung cells, the LD50 values found for Hfn in this study place the A549 cell line in
line with a list of several other known human carcinomic (or immortal) cell lines to
which Hfn is antiproliferative. Thus, the A549 cell line may be added to this list and
likely shares the same mechanism of action in Hfn-induced apoptosis (induction of
mitochondrial-mediated pathway) (Schempp et al., 2002; Medina et al., 2006).
Hypericin, Pseudohypericin, and M. JLS Treatments. The Hpn and Phn
treatments were only assayed with the Pierce BCA protein assay, which showed no
significant viability effect at 28 µg/ml (Hpn) and 61 µg/ml (Phn). The Hpn treatment did
reach a LD50 value (based on the “time 0” value) at 72 hr, though this value had a
relatively high standard deviation. The Phn treatment reached a LD50 value at 48 hr, but
cell numbers were above that value the following day. However, the error in these ranges
makes further testing of these compounds necessary, but merited, as hypericin is known
to cause photosensitization and cell death in mammalian cells through high singlet
oxygen yield (Agostinis et al., 2002). Also, the effect of combinations of the hypericins
(with each other and with Hfn) on A549 viability merits investigation.
No statistically significantly different effect from the controls was seen in the
A549 samples treated with M. JLS (at 5x106 bacteria/cm2). The bacteria were added to
media containing penicillin/streptomycin (10K U/ml and 10K µg/ml, respectively) and
did not produce colonies after plating onto antibiotic-free LB agar plates. The bacteria
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were introduced in the same range as was used in similar studies (Lin et al., 1998). As
the M. JLS cells were nonviable, these results should be similar to the effect that would
have been gained from adding mycobacterial cell components.
Mycobacterial Growth in Ham’s Media
The results of the growth test for all the bacterial strains from the MBC studies
are shown in Table 5.3. No strains grew in media containing Pen-Strep, and only M. JLS
and E. coli grew in the antibiotic-free media. These results may be of use for future
studies on the effects of these strains on A549 cells when alive in culture, since the
presence of dead M. JLS cells did not have a significant viability effect.
Conclusions
The studies performed on the effect of SJW MeOH extract and compounds show
that MeOH does not have a significant effect on A549 cell viability at or below 3% (v/v).
Hpn and Phn concentrations of 28 µg/ml and 61 µg/ml, respectively, do not permanently
or consistently lower the A549 cell count below LD50 values. Hfn has a statistically
significant effect on A549 cell viability at concentrations from 6 µg/ml to 46 µg/ml and
does not at 3 µg/ml or lower. Hfn also causes cell death at concentrations ≥11 µg/ml,
with an LD50 of 3-6 µg/ml; this value is similar to a list of other carcinomic cell lines
known to be sensitive to Hfn-induced apoptosis through a mitochondrial-mediated
pathway, and these results justify the addition of the A549 cell line to that list. The
repeated failure of trypsin to detach/disaggregate crude extract-treated A549 cells from
the plate surface and from each other suggests that either the crude extract contains a
trypsin-inhibiting compound or that the extract somehow prevents cell detachment after
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death. The presence of nonviable M. JLS cells, at a concentration of 5 x 106 cells/cm2,
does not show a statistically significant viability effect on A549 cells. M. JLS and E.
coli grow in antibiotic-free Ham’s media.
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Table 5.1 Statistical analysis parameters for the A549 samples from the
direct cell count study. Degrees of freedom show how many values are free
to vary in the final statistical calculation. Partial R2 values show what
proportion a treatment or interaction has on the final outcome, and these
values add to 1. Additive (what was added to the A549 cells) had the
greatest effect, followed by the interaction of additive and time, followed by
time. The F-value is used to determine the p-value, which if under 0.05, is
considered statistically significant.
	
  
Time	
  
Additive	
  
Time*Additive	
  

Deg.	
  Freedom	
  
3	
  
9	
  
27	
  

Partial	
  R2	
  
0.24	
  
0.441	
  
0.282	
  

F-‐value	
  
86.36	
  
53.02	
  
11.31	
  

Pr>F	
  (p-‐value)	
  
<0.0001	
  
<0.0001	
  
<0.0001	
  

Table 5.2 Ryan-Einot-Gabriel-Welsh q (REGWQ) test for
A549 cell treatments that received direct cell counting.
Treatments are listed in descending order by mean. Groups
of each letter are statistically significantly different from
other groups.
Additive	
  
MeOH	
  control	
  
No-‐MeOH	
  control	
  
M.	
  JLS	
  
Hfn	
  3	
  µg/ml	
  
Hfn	
  6	
  µg/ml	
  
Hfn	
  23	
  µg/ml	
  
Hfn	
  11	
  µg/ml	
  
Hfn	
  46	
  µg/ml	
  
Crude	
  2.6	
  mg	
  extract/ml	
  
Crude	
  1.3	
  mg	
  extract/ml	
  

Mean	
  
45.9	
  
45.2	
  
44.2	
  
39.1	
  
24.2	
  
22.0	
  
21.0	
  
13.8	
  
11.5	
  
9.9	
  

N	
   REGWQ	
  Grouping	
  
8	
  
A	
  
	
  
8	
  
A	
  
	
  
8	
  
A	
  
	
  
8	
  
A	
  
	
  
8	
  
	
  
B	
  
8	
  
C	
  
B	
  
8	
  
C	
  
B	
  
8	
  
C	
  
D	
  
8	
  
	
  
D	
  
8	
  
	
  
D	
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Table 5.3 Growth results in Ham’s media of all
Mycobacterium isolates used in the MBC studies. Growth
is marked by a “Y” or “N” for yes or no.
Strain	
  
M.	
  JLS	
  
M.	
  KMS	
  
M.	
  MCS	
  
M.	
  smegmatis	
  
M.	
  phlei	
  
E.	
  coli	
  
B.	
  subtilis	
  

Containing	
  Pen-‐Strep	
  
No	
  Antibiotic	
   (100	
  U/ml,	
  100	
  µg/ml)	
  
Y	
  
N	
  
N	
  
N	
  
N	
  
N	
  
N	
  
N	
  
N	
  
N	
  
Y	
  
N	
  
N	
  
N	
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Figure 5.1 The improved Neubauer Bright-Line Hemacytometer setup
(www.hausserscientific.com). The surface is 100 µm deep. The four 1-mm2
sections (highlighted in red) were used to calculate A549 cell concentration, and
each section gives cells/100 nl. The four smaller, 0.04-mm2 sections
(highlighted in blue) were used to calculate bacterial concentration, and each
section gives cells/4 nl.
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Figure 5.2 Pierce BCA total protein assay for the effect of MeOH on A549 viability.
No statistically significant viability differences were seen. Cells were assayed at
concentrations from 0-3% and harvested at 72 hr exposure. Error bars are SD.
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Figure 5.3 Pierce BCA total protein assay results for Hpn, Hfn, Phn, and SJW MeOH
crude extract at concentrations found in the 4.46 mg extract/ml crude extract. Due to cell
staining by the crude extract, the protein assay gave OD readings that were much higher
than the controls. Imprecise results were seen with the other samples. Cell death was
seen, however, in the Hfn sample. Error bars are SD.
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Figure 5.4 Direct cell count results (2 replicates, 4 counts each) for effect of dead M.
JLS cells, SJW MeOH crude extract, and Hfn on A549 cell viability. Cell death occurred
with the 1.33 and 2.66 mg extract/ml crude extract concentrations and in the 11, 23, and
46 µg/ml Hfn concentrations. Cell death did not occur in the no-MeOH/SJW control,
MeOH control, or M. JLS samples. The Hfn LD50 value was 3-6 µg/ml. Error bars are
SD. Corresponding images are seen in Figures 5.5-5.7.
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Figure 5.5 24-hr exposure of A549 cells to dead M. JLS
cells (5x106 bacteria/cm2), crude extract (1.33 and 2.66
mg extract/ml), and Hfn (3, 6, 11, 23, and 46 µg/ml).
Cell death occurred in the crude extract samples and in
the three highest-concentrated Hfn samples, with a Hfn
LD50 of 3-6 µg/ml (5.6-11.2 µmol/L). Cell morphology
shown in bottom right of each image.
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Figure 5.6 48-hr exposure of A549 cells to dead M. JLS
cells (5x106 bacteria/cm2), crude extract (1.33 and 2.66
mg extract/ml), and Hfn (3, 6, 11, 23, and 46 µg/ml).
Cell death occurred in the crude extract samples and in
the three highest-concentrated Hfn samples, with a Hfn
LD50 of 3-6 µg/ml (5.6-11.2 µmol/L). Cell morphology
shown in bottom right of each image.
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Figure 5.7 72-hr exposure of A549 cells to dead M. JLS
cells (5x106 bacteria/cm2), crude extract (1.33 and 2.66
mg extract/ml), and Hfn (3, 6, 11, 23, and 46 µg/ml).
Cell death occurred in the crude extract samples and in
the three highest-concentrated Hfn samples, with a Hfn
LD50 of 3-6 µg/ml (5.6-11.2 µmol/L). Cell morphology
shown in bottom right of each image.
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CHAPTER 6
ENGINEERING APPLICATIONS AND FUTURE CONSIDERATIONS
Several potential engineering applications or considerations of this research, as
well as possible future directions, are listed below:
Engineering Applications and Considerations
1. Investigating the optimal droplet size of Hfn aerosols for delivery to the lungs.
2. Micro- or nano-encapsulating SJW compounds in a dissolving suspension,
looking into the possibility of a time-released treatment.
3. Looking into the design of encapsulation materials, taking into consideration
lipophilicity, dissolving rate, and surface wetting (for cell adhesion) parameters.
A polymeric material such as poly (lactide-co-glycolide) (PLGA) could be used.
4. Undertaking a direct focal delivery study of SJW-compound-encapsulation
particles, engineering the surface of the particles to preferentially adhere to the
cell surfaces of TB granulomas. This would enable the use of higher medication
concentrations and minimize toxicity to healthy cells.
5. Investigating mass transfer rates of SJW compounds in cell culture, developing
mass transfer vs. penetration depth charts.
6. Determining values for exposure time and frequency of treatment with SJW
compounds to adequately repress or kill Mycobacterium strains in lung cell
models.
7. Investigating the surface-coating rates of nebulized liquid, microparticles, and
nanoparticles containing SJW compounds. This investigation could also look into
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developing models which would predict necessary medication flow rates to coat
only a given percentage of cell surface area at a time; the idea of this would be to
allow oxygen transfer to the lung cells while still uniformly coating the cell
surface over time.
8. Employing the use of fluorescent particles (such as quantum dots that fluoresce in
the tissue-transmission range) that are attached to mycobacterial-specific
antibodies for locating mycobacterial infection sites in the lungs. Successes in
this area could reduce or eliminate the need for using X-rays in TB screening.
9. Using mycobacterial-specific antibodies in materials used in targeted drug
delivery (such as the above-mentioned nanoparticles) to mycobacteria in the
lungs. Lung-cell models treated with dead Mycobacterium cells (or live if using
non-antibiotic-containing media), which have been shown to be a viable option as
a result of this study, could make adequate models.
10. Developing a cancer-screening method that detects Hfn metabolites. It is known
that Hfn affects carcinomic cells, and it may be possible that only these types of
cells metabolize this compound.
11. Investigating systemic Hfn treatment parameters in animals (after appropriate in
vitro screening) to investigate Hfn effectiveness in metastatic prophylaxis.
12. Looking into the viability (based on successes in the previously mentioned
applications in this section) of a home-treatment option for TB patients.
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Future Work Recommendations (In Order of Priority)
1. Performing viability and inflammatory assays of pure Hfn against primary lung
cells and other primary human cells to determine if the Hfn levels at which
inflammation or cell death occurs is sufficiently above the Hfn levels known to
cause apoptosis in carcinomic cell lines. Such studies should also include other
SJW compounds to investigate their effects. Viability assays would likely include
direct cell count and live-dead fluorescence assays. Inflammatory assays would
likely include cell membrane integrity, metabolic function, and interlueken-8
assays. Findings from such studies would be beneficial for both
antimycobacterial and cancer research.
2. Narrowing in on the mechanism of action for Tween 80 repression of Hfn
inhibition of mycobacteria. Such studies would include treating a nonmycobacterial, Hfn-susceptible strain (such as B. subtilis) with the same Hfn
concentration and variable Tween 80 concentrations (similar to the study shown
in Figure 4.21). A variation of this study that would use mycobacteria but other
known mycobacterial antibiotics instead of Hfn should also be done to see if the
Tween 80 effect is Hfn-specific. Antibiotics chosen should include those that
affect the cell wall more directly (INH, EMB) and those that affect the cell in
other ways (RIF, SM). Findings from this study may also contribute to
discovering the Hfn mechanism of action if the Tween 80 Hfn repression is due
only to modification of outermost layer of the cell wall.
3. Investigating the surfactant that is known to be present in the lungs (Foster et al.,
1998) and assaying this surfactant (or surfactants other than Tween 80) in SJW
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inhibitory assays against mycobacteria to see if the Tween 80 Hfn-repression
effect seen with M. JLS is specific to Tween 80. This would help determine if
Hfn treatment of TB through inhalation is a viable option.
4. Conducting further studies to investigate the mechanism of action for SJW crude
extract and Hfn in both mycobacteria and A549 cell inhibition/toxicity. Such
studies would likely employ the use of microarray technology to understand
genetic induction/repression with SJW exposure. Studies that assay for free
mycolic acids or several other specific cell wall components may also be
employed; such techniques have been used in determining the mechanisms of
action with other mycobacterial antibiotics (Dover et al., 2008). Another method
may be to compare SEM images of bacteria treated with other mycobacterial
antibiotics to images of bacteria treated with SJW compounds.
5. Including binary or tertiary combinations of SJW compounds in assays that
investigate their synergistic effects on both bacteria and lung cells. It is possible
that a combination of compounds has a more potent inhibitory or bactericidal
effect than Hfn alone. The SJW inhibitory studies presented in Chapter 4 showed
a more rapid inhibition response with the crude extract than with pure Hfn, even if
both had the same Hfn concentration; combination studies would be a first step to
discovering the reason for this. No such study has been seen in literature.
6. Investigating the stability of Hfn in blood. Such understanding would be critical
for correct dosage administration. It would also be one of the first steps of
investigation for the possibility of using Hfn for metastatic cancer treatment.
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7. Comparing the effects of SJW extracts of different organic solvents in more detail
than was done in this study. One such solvent would be ethyl acetate, which was
shown in this study to produce a lighter-colored extract and may make
colorimetric assay a more feasibly option. As colorimetric assays are often less
laborious than direct CFU or cell counting methods, this may make many aspects
of SJW research more efficient.
8. Investigating the cause of trypsin-EDTA ineffectiveness in detaching A549 cells
after treatment with the SJW crude extract. It may be possible that the MeOH
extract contains a trypsin inhibitor, which may be useful for other biotechnology
applications.
9. Developing an HPLC preparative method to obtain greater quantities of SJW
active compounds. This would make pure compound studies possible in greater
volumes of media, making concentration and volume variability due to
evaporation less of an issue. It would also allow the assaying of higher
concentrations of the pure compounds against bacteria and mammalian cells.
10. Refining the photoconversion/photodegradation parameters for SJW crude
extracts, narrowing in on the Hpn/Phn-converting and Hfn-degrading
wavelengths. As seen from the Hfn degradation study in Chapter 5, using specific
light conditions are important to maintaining accurate concentrations. Knowing
specific wavelengths at which degradation is avoided may eliminate unnecessary,
burdensome precaution (such as working in overly dark conditions).
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Luria (LB) Broth and Agar
LB Broth
LB broth was prepared by dissolving 10 g Bacto Tryptone (BD, Fisher,
Pittsburgh, PA), 5 g Bacto yeast extract (BD, Fisher, Pittsburgh, PA) and 10 g sodium
chloride (NaCl) (Fisher, Pittsburgh, PA) in 1 L ddH2O. This solution was covered in foil
and autoclaved at 121°C for 30 min. The broth was stored at room temperature
LB Agar
If preparing agar LB for plates, 15 g Difco agar (BD, Fisher, Pittsburgh, PA) was
added to the mixture above before autoclaving at the same temperature and time. For
agar plates, the agar was gently swirled immediately after autoclaving and allowed to
cool in a laminar flow hood to approximately 55°C. The agar was then poured into
100x15 mm Petri dishes (Fisherbrand, Fisher, Pittsburgh, PA) in aliquots of
approximately 25 ml. After cooling for about 30 min with the lid cracked open to allow
the plates to dry, the plates were placed in a bag and kept at 4°C until use.
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Middlebrook (MB) 7H9 Broth and 7H10 Agar
MB Broth
To make MB 7H9 broth, 4.7 g of Difco Middlebrook 7H9 powder (BD, Fisher,
Pittsburgh, PA) was suspended in 900 ml ddH2O (containing 2 ml glycerol or 0.5 g
Tween 80, if desired) and autoclaved at 121ºC for 10 min. When media had cooled to
45ºC, 100 ml Middlebrook ADC Enrichment (BD, Fisher, Pittsburgh, PA) was added
aseptically.
MB Agar
To make MB 7H10 agar, 19 g of Difco Middlebrook 7H10 powder (BD, Fisher,
Pittsburgh, PA) was suspended in 900 ml ddH2O containing 5 ml glycerol. After mixing,
this solution was heated until boiling and boiled for 1 min to dissolve the powder. It was
then autoclaved at 121ºC for 10 min. The agar was gently swirled immediately after
autoclaving to resuspend the agar. After cooling to 50-55ºC, 100 ml Middlebrook OADC
Enrichment (BD, Fisher, Pittsburgh, PA) was added aseptically. Agar was then poured
into plates in aliquots of approximately 25 ml. After cooling for about 30 min with the
lid cracked open to allow the plates to dry, the plates were placed in a bag and kept at 4°C
until use.
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A549 Media Preparation
Nutrient mixture F-12 Ham’s media in powder form was obtained from SigmaAldrich (N3520) (St. Louis, MO). Each bottle was formulated for 1 L media. The
powder from one of these bottles was added to 900 ml purified H2O, and the residual
powder from the bottle was rinsed and added to the solution. Sodium bicarbonate
(NaHCO3), 2.5 g, was added, and the pH was lowered to between 7.1 and 7.2 using 1N
hydrochloric acid (HCl). Another 100 ml purified H2O was added. This solution was
then 0.2-µm filtered and stored at 4ºC if it was not going to be used within two months
(could be stored up to six months). If media was needed soon, fetal bovine serum (FBS)
(Invitrogen) was added at 10% the final media volume along with 100X PenicillinStreptomycin solution (10K U/ml and 10K μg/ml, respectively, from Thermo Scientific –
Fisher) at 1% the final volume prior to use.
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SEM Fixation Protocol
The cell fixation protocol used by Drs. TC and FenAnn Shen for the SEM images
is as follows:
Reagents:
1. 2% buffered gluteraldehyde
23.83 grams HEPES in 40 ml 50% glutaraldehyde. Bring to 1L with DI water.
-OR23.83 grams HEPES in 250 ml 8% glutaraldehyde. Bring to 1L with DI water. Bring
pH to 7.0.
Note: Can use 30.24 g PIPES or 21.402 g sodium cacodylate trihydrate (toxic,
contains arsenic) in place of HEPES. PBS can also be used but leaves salt crystals.
2. 1-2% osmium Tetroxide
4 ml 4% osmium tetroxide, 4 ml 0.4M HEPES (95.32 g in 1L DI water), and 8 ml DI
water. pH to 7.0.
Note: If PIPES is used in 2% buffered glutaraldehyde, then use 120.96 g PIPES in 1 L
DI water. If cacodylate used, then use 85.608 g sodium cacodylate trihydrate in 1 L
DI water.
3. 0.1M HEPES Buffer
23.83 grams HEPES in 1 L of DI water. pH to 7.0
Note: If PIPES used in 2% buffered glutaraldehyde, then use 30.24 g PIPES in 1 L DI
water. If sodium cacodylate trihydrate is used, then use 21.402 g sodium cacodylate
trihydrate in 1 L DI water.
4. 50%, 70%, 95%, and 100% EtOH
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Protocol
1. Fix sample with 2% buffered glutaraldehyde. Fixative should be 10 to 20 times the
volume of the sample. Let sit for 2 hr minimum.
2. Rinse with 0.1 M HEPES buffer 3 times for 5 min each with gentle agitation.
3. Post fix in 1-2% osmium tetroxide for 1 hr.
4. Rinse with 0.1 M buffer 3 times for 5 min each.
5. Alcohol series dehydration:
- 50 % EtOH, 2 times for 10 min each with agitation.
- 70 % EtOH, 2 times for 10 min each with agitation.
- 95 % EtOH, 2 times for 10 min each with agitation.
- 100 % EtOH, 3 times for 15 min each with agitation.
6. Keep in fridge until ready to dry and sputter coat.
7. Dry.
Option A: Use a critical point dryer.
Option B: Chemical drying
1. (2 parts 100% EtOH : 1 part HMDS) for 15 min.
2. (1 part 100% EtOH : 1 part HMDS) for 15 min.
3. (1 part 100% EtOH : 2 parts HMDS) for 15 min.
4. HMDS alone for 15 min, 3 times.
5. Let the last HMDS evaporate in a fume hood overnight.
8. Mount samples on specimen stubs, sputter coat and view.
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Notes
1. HMDS, glutaraldehyde, and osmium tetroxide are all toxic. They need to be put in
separate bottles to be disposed.
2. The solid container that touches HMDS, glutaraldehyde, or osmium tetroxide needs to
be put in a solid chemical waste box to be disposed.
3. HEPES is a buffer solution to wash off other chemicals without changing the pH
values.
4. Glutaraldehyde is to stop biological process in an organism – chemical fixing.
5. Osmium tetroxide is to keep structure integrity when the organism is fixed.
6. HMDS is a chemical drying agent to remove water. Thus, the final step does not need
water in the HMDS solution.

